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1. INTRODUCTION 
1.1．Gene therapy 
Gene therapy is the use of genetic information to treat human diseases by the selective 
delivery of DNA into a patient’s cells defective or missing DNA sequences. Gene 
therapy was first conceptualized by Theodore Friedmann and Richard Roblin [1]. 
Martin Cline conducted the first gene therapy trial involving recombinant DNA in 1980. 
The first successful FDA approved gene therapy study was targeting ADA-SCID in the 
United States in 1990. Since then, the number of studies for gene therapy rapidly 
increased to > 2.000 completed or ongoing trials today. AAV-based gene therapy was 
first applied in 1997, and a decade later [2] reported improvement of human eyesight by 
using an AAV-mediated gene transfer.  
1.1.1. Viral vectors 
Viral and non-viral vectors are used for targeted gene delivery. Viral vectors are the 
most efficient for gene therapy, but their approach is limited by their immunogenicity, 
the available packaging size of DNA and their oncogenic potential. The most popular 
viral vectors for gene delivery are adenovirus [59], adeno-associated virus [14], 
retrovirus and lentivirus [60]. In principle, they display varying features: For example, 
the adenovirus has a naked coat, an icosahedral capsid, lacks virion polymerase, but 
provides a transient transgene expression and a packaging capacity of 7.5 kb. The 
adeno-associated virus has a naked coat, an icosahedral capsid, no virion polymerase, 
but provides long lasting transgene expression, and a packaging capacity of 4.5 kb. In 
contrast, retroviruses/lentiviruses have an enveloped coat, an icosahedral capsid, possess 
a virion polymerase, insert into the host genome, and provide a packaging capacity of 8 
kb (Table 1). 
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   Adenovirus  AAV  Retro-/Lenti-virus  
Family  Adenoviridae  Parvoviridae  Retroviridae  
Coat  Naked  Naked  Enveloped  
Capsid  Icosahedral  Icosahedral  Icosahedral  
Genome  dsDNA  ssDNA  ssRNA(+)  
Virion polymerase  Negative  Negative  Positive  
Virion diameter  70 - 90 nm  18 - 26 nm  80 - 130 nm  
Genome size  39 - 38 kb  5 kb  3 - 9 kb  
Infection/tropism  Dividing and non-dividing cells  Dividing and non-dividing cells  Dividing cells  
Host genome interaction  Non-integrating  Non-integrating  Integrating  
Transgene expression  Transient  Potential long lasting  Long lasting  
Packaging capacity  7.5 kb  4.5 kb  8 kb  
 
Table 1 | Characterization of viral vectors. dsDNA, double-stranded DNA; ssDNA, single-stranded 
DNA. (Modified from Gene Therapy Net; http://www.genetherapynet.com/viral-vectors.html). 
1.1.2. Non-viral vectors 
Non-viral vectors possess several advantages compared to viral vectors, such as large 
capacity, a low production costs, a low immunogenicity as well as a low toxicity. The 
main limitation of non-viral vectors is their low continuous transfer efficiency compared 
to viral vectors in gene delivery. Nonetheless, recent studies of non-viral vectors show 
substantial progress [4]. 
Currently used non-viral vectors are inorganic, polymer, lipid-based or hybrid [8]. 
Specially, inorganic particles including gold nanoparticles, calcium phosphate, magnetic 
nanoparticles, and carbon nanotubes (CNTs) are commonly used for gene delivery 
materials. These particles possess advantages, such as easy preparation, quick 
transfection, wide availability, and high transfection efficiency. But they are toxic, 
non-biocompatible and imply low transferring efficiency.  
Polymer-based particles include cationic polymer, polysaccharide particle, 
polyethylenimin (PEI) polymers, dendrimers, poly lactic-co-glycolic acid 
(PLGA)-based nanoparticles, and poly-ion complex micelles (PICs). In addition to other 
advantages, they display high protection against enzymatic degradation, easy 
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preparation, low toxicity and a high cationic potential. But they also feature low 
biodegradability and low transferring efficiency.  
Cationic lipids, cationic emulsions, and cationic liposomes are lipid-based particles 
commonly utilized for gene delivery to target cells. These particles have safe 
preparation, low immunogenicity, but a toxic in high dose, and difficult to prepare as 
well as transfer efficient. 
Hybrid particles contain two groups, such as liposome-polycation-DNA (LPD) particles 
and multilayered nanoparticles. These particles consist of polyplexes and liposomes, 
called as lipopolyplexes. Most of the polyplexes contain complexes of polymers with 
DNA, e.g. cationic polymers (such as NH2 surfaced-dendrimers) and their production is 
regulated by ionic interactions. One advantage compared to other non-viral vectors is 
their high transfection efficiency, similar to viral vectors. The properties, advantages, 
and disadvantages of these non-viral vectors are presented in Tables 2 [8]. 
Vectors Toxicity Advantages Disadvantages 
Inorganic 
Frequently 
toxic 
Short time of transfection, easy preparation, wide 
availability, rich functionality, high transfection 
efficiency, potential capability for targeted delivery and 
controlled release 
Most of them are instable, toxic 
and non-biocompatible 
Polymer 
Low 
toxicity 
Small size, narrow distribution, more stability, high 
protection against enzymatic degradation, low toxicity 
and high cationic potential 
Low biodegradability, 
low efficacy 
Lipid Toxic Safe preparation, low immunogenicity 
Toxicity at high dose, difficult 
preparation, low transformation 
efficiency 
Hybrid 
Low 
toxicity 
Improved the loading dose of DNA cellular uptake, 
controlling the release of the DNA and target delivery 
compared to other non-viral vectors 
Toxicity at very high dose 
 
Table 2 | Different type of non-viral vectors in gene delivery. Toxicity; Cellular toxicity. (Modified 
from Dizaj et al., Nanoscale Research Letters 2014 [8]). 
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1.2．Adeno-associated virus 
Given the range of vector systems described above, adeno-associated viruses are a 
promising vector system for human gene therapy, since they are not known for human 
pathogenity, provide a long lasting effect at low immunologic side effects. The first 
serotype was discovered in 1965, isolated from a contaminant of simian adenovirus 
preparations [5]. AAVs are small viruses with a non-enveloped icosahedral capsid of a 
size between 18 ~ 26 nm (Figure 1) [6]. Although about 40-60% (depending on regional 
differences) of adults are sero-positive for AAV serotype 2 (AAV2), the infection has 
not been associated with any symptoms or disease. Because AAV serotypes are 
members of the Parvoviridae family and belong to the genus Dependovirus, they require 
a helper virus, such as adenovirus, to support productive infection and replication. The 
capsid structure controls in different tissues specificity and transduction efficiency [12]. 
The tropisms of each AAV serotypes are indicated as in Table 3. 
 
 
 
 
 
 
 
Figure 1 | Transmission electron microscopy image of AAV2 and Ad5. A, AAV2 and Ad5 particles in 
the nucleus of a HeLa cell at 48 hours after co-infection. Magnification: × 15,000. B, AAV2 virions in a 
HeLa cell at 48 hours after co-infection with Ad5. Magnification: × 40,000. (Adapted from Gonçalves 
MA, Virology Journal 2005 [6]). 
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Serotype Origin Receptor Co-receptor 
AAV1 Muscle, CNS 2.3N/2,6N-sialic acid Unknown 
AAV2 Muscle, liver, Kidney HSPG FGFR-1, integrin, HGFR, LamR 
AAV3 Inner ear HSPG FGFR-2, HGFR, LamR 
AAV4 CNS, Eye 2.3O-sialic acid Unknown 
AAV5 Lung, CNS, Photoreceptor cells 2.3N-sialic acid PDGFR 
AAV6 Skeletal muscle 2.3N/2,6N-sialic acid EGFR 
AAV7 Skeletal muscle N-sialic acid PDGFR 
AAV8 Heart, Liver, Pancreas, Skeletal muscle Unknown LamR 
AAV9 Heart, Liver, Skeletal muscle, Lung N-galactose LamR 
 
Table 3 | Tropisms, receptors and co-receptors of AAV serotype vectors. HSPG; heparan sulfate 
proteoglycan, FGFR; Fibroblast growth factor receptor, HGFR; hepatic growth factor receptor, PDGFR; 
platelet derived growth factor receptor, LamR; 37/67 KD laminin receptor, EGFR; epidermal growth 
factor receptor, CNS; Central nervous system. (Modified from Zhijian Wu et al., Molecular Therapy 2006 
[10] and Hyun-Joo Nam et al., J Virol 2007 [12]). 
1.2.1. Structure of AAV 
The virion shell of AAV has as a small (about 18~26 nm), naked coat, a T=1 
icosahedral capsid, negative virion polymerase, and a single stranded DNA genome 
(capacity ~4.7 kb). The AAV genome is packaged into T=1 icosahedral capsids 
consisting of 60 subunits of capsid proteins (CPs). The inverted terminal repeats (ITRs; 
~145 kb) flank the two viral open reading frames (ORFs) rep (replication) and cap 
(capsid) encoding non-structural and structural proteins [6]. The ITRs are required for 
genome replication and packaging. The rep non-structural ORF, encodes four 
replication proteins responsible for site-specific integration, nicking, and helicase 
activity. The cap structural ORF contain three viral proteins (VPs): VP1, VP2 and VP3, 
which assemble the capsid by 2-, 3-, and 5-fold symmetry-related interactions in 
proportions of about 1:1:10 (Figure 2) [7].  
 
 
 
Introduction 
 9  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 | Three-dimensional structure of AAV capsid and variable regions. A, Radially color-cued 
(from capsid center to surface: blue-green-yellow-red; ~110–130 Å) of the AAV1 capsid generated from 
60 VP monomers (RCSB PDB # 3NG9). The approximate icosahedral two-, three-, and five-fold 
symmetry axes are as well as the AAV capsid surface features are indicated by the arrows and labeled and 
indicated by the filled oval, triangle, and pentagon, respectively in (A & B). B, The capsid surface of 
AAV2 with VR-I to VR-IX colored (I: purple, II: blue, III: yellow, IV: red, V: black, VI: hot pink, VII: 
cyan, VIII: green, and IX: brown) and labeled as in (B & C). C, A ribbon diagram representation of the 
ordered over lapping VP3 monomer region of AAV1. The conserved β-barrel core motif (βBIDG-βCHEF, 
gray), conserved αA helix, DE loop (between βD and βE), HI loop (between βH and βI), VR-I to VR-IX 
are colored as in (B). The N and C labels are the N- and C-terminal ends of the ordered VP region, 
respectively. The (A) image was generated using the Chimera program. (B & C) were generated with the 
PyMOL program. (Adapted from Tseng et al., Front Immunol 2014 [7]). 
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Three-dimensional structures have been determined for several serotypes of AAV (about 
AAV1-AAV9) by X-ray crystallography or cryo-reconstruction. These AAV serotypes 
are representatives of the over 100 AAV genomic isolates and 13 human and non-human 
serotypes. The AAVs have a sequence similarity that ranges from ~55 to 99% [7, 9, 12, 
21, 22]. These capsid proteins of 60 subunits have been positioned by three rules 
(Figure 2A, B): 
1. They assemble the capsid in 2-, 3-, and 5-fold symmetry-related interactions in 
proportions of about 1:1:10 [9]. 
2. 3-fold axes and 5-fold axes are at vertices joining 3-fold protrusions and 5-fold 
cylinders, respectively, and 2-fold depressions bisect neighboring 3-folds [7]. 
3. The 2-, 3-, 5-fold axes from a triangle (2-fold axes, as dimple, surrounding a 
cylindrical channel at the 5-fold axes, as canyon, and protrusions surrounding 
the 3-fold axes) and It may be repeated sixty-fold with icosahedral symmetry 
operators to generate the entire capsid [9, 12].  
 
The ribbon diagram of VP region consists of a eight stranded anti-parallel (bB-bI) 
β-barrel core motives, conserving alpha helix (αA), DE loop, HI loop, VR-I to VR-IX 
(Figure 2C). These VRs contribute to local topological differences between the AAV 
capsid surfaces. They assemble such that VR-I, III, VII, and IX contribute to the 
2/5-fold wall; VR-VI and VR-VII form their base; VR-IV, V, and VIII form the top of 
the 3-fold protrusion and VR-II forms the top of the 5-fold channel. Furthermore, they 
are dictate that including receptor attachment, antigenic reactivity, transduction 
efficiency, and functional differences [12, 13, 21, 22]. 
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1.2.2. The tissue tropism of AAV serotypes 
The transduction of AAV starts by binding to a receptor and/or co-receptor complex. 
The course of AAV transduction requires five steps (Figure 3): (1) cellular attachment, 
(2) initial interaction with receptors or co-receptors on the cell surface molecules, cf. 
(Table 3), (3) internalization of virion by the host cell, virus intracellular trafficking 
through the endosomal compartment, escape of the virus from the endosome, and virion 
uncoating, (4) entry into the nucleus and release of the single stranded vector genomes 
with subsequent viral genome conversion from single stranded to a double stranded 
DNA, and (5) chromosomal integration before gene expression. Of note, hybridization 
of complementary input genomes can occur from a double stranded template, or (6) 
deletion integration and gene expression. 
 
 
 
 
 
 
 
 
Figure 3 | Cell entry and trafficking of AAV. AAV enters the cell through receptor-mediated 
endocytosis. The transduction by AAV vectors showing six steps. The AAV vector particles are binding 
to cellular attachment (1) and an initial interaction with a variety of receptors or co-receptors on the cell 
surface molecules (2), as in (Table 3). Internalization of virion (3), nuclear entry and release of the single 
stranded vector genomes (4). Chromosomal integration before gene expression, and/or hybridization of 
complementary input genomes can occur from a double stranded template (5), or deletion integration and 
gene expression (6). (Modified from Russel DW et al., Blood 1999 [11]). 
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The AAV pseudotyping experiments demonstrate that the varying cell tropism and 
transduction efficiencies are dictated by specific capsid viral protein (VP) amino acids 
[7, 9, 12, 21, 22]. Each serotype of AAV capsids mediates binding to a cellular receptor 
before cell entry (Table 3). For example, AAV serotype 2 makes its initiates first 
contact with the target cell by attaching to the receptor heparan sulfate proteoglycan 
(HSPG), which might be enhanced by co-receptors (as αVβ5 integrin, fibroblast growth 
factor receptor-1; FGFR-1, and hepatocyte growth factor receptor; HGFR) [10, 11, 21]. 
Each AAV serotype has specific binding receptors. However, the target specificity may 
be altered by AAV surface modification [15, 21], e.g., engineering of AAV2 capsid 
virion protein. Thus, deletion of heparan binding site (R484 and R585) diminishes 
hepatic expression and augments cardiac expression (Figure 4). 
 
 
 
 
 
 
 
 
 
Figure 4 | In vivo distribution of wild-type rAAV and rAAV mutant (R484E/R585E) in mouse 
tissues. Luciferase activities in different organs after intravenous injection of 1011 wild-type capsids or 
rAAV mutated in R484E and R585E, 3 weeks post infecion. Luciferase activities are depicted in relative 
light units (RLU) per milligram of protein. Error bars indicate standard deviations. (Adapted from A. 
Kern et al., J Virol 2003 [21]). 
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1.3．Nanoparticles 
Surface modification of AAV vectors comprises several possibilities, including peptide 
expression at privileged sites of the vector capsid [49] or shuffling of the capsid gene 
sequences of various strains [85]. A novel and promising approach consists of coating 
of vector capsids with dendrimeric nanoparticles. 
Dendrimers are repetitively branched macro molecules (three-dimensional polymers) 
with spherical, branched structures. Commonly used dendrimers are polyamines, 
polyamides, or polyesters. These molecules possess the central core, branches (which 
give rise to dendrimer generations) and surface peripheries (Figure 5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 | Schematic representation of polyamidoamine (PAMAM) dendrimers. A, In contrast to 
traditional polymers, dendrimers are unique core-shell structures possessing three basic architectural 
components: (1) a core, (2) an interior of shells (an increase in generation number (G0 to G5) consisting 
of repeating branchpoints, and (3) surface functional groups. B, The characterization of generation of 
PAMAM. MW; Molecular Weight (Modified from Donald A et al., Materialstoday 2005 [34]). 
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The first report of repetitive growth with branching was provided by Buhleier in 1978 
[31]. The polyamineamide (PAMAM) dendrimers are the most common group of 
dendrimers suitable for applications of nano-medicine. These macromolecules 
constitute a class of hyperbranched polymers developed by Tomalia in 1979 [32]. 
PAMAM nanomolecules are readily used in non-viral gene delivery system for 
enhancing transduction efficiency (Figure 6) [33, 34].  
PAMAMs are highly variable in their molecule structure. An increase in generation 
number (G0 to G10) is provided by interiors. Five core types (cystamine, 
diaminobutane, diaminohexane, diamonododecane, and ethylenediamine core), and nine 
functional surface groups (amine, amidoethylethanolamine, amidoethanol, sodium 
carboxylate, succinamic acid, hexylamide, carbomethoxypyrrolidinone, 
tris-hydroxymethyl-amidomethane, and poly-ethyleneglycol) add to their variability 
(Figure 5A). 
 
 
 
 
 
 
 
 
 
Figure 6 | Factors affecting nanoparticle cellular uptake. A, Given similar surface characteristics, 
smaller nanoparticles are more efficiently internalized than larger nanoparticles. B, Cationic surface 
nanoparticles are preferentially taken up by cells. C, Cell specific targeting by a surface 
modified-nanoparticles (target cell membrane specific ligand conjugated ligands). D, Rapid uptake by 
conjugating protein transduction domains to the surface of the nanoparticle. E, Application of 
oligodeoxynucleotide (ODN) was found to aid in specific internal cellular localization. F, Positive surface 
charged nanoparticles can escape from endosomes. (Adapted from K. Ted Thurn et al., Nanoscale Res 
Lett 2007 [30]). 
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Furthermore, these PAMAMs display various external charge patterns: there are 
positively charged amino-termini (cationic), neutral hydroxyl-termini (neutral), or 
negatively charged carboxyl-termini (anionic) provided by the surface molecules [37]. 
The PAMAMs of generation 2 (PAMAM G2: 3,348 MW) and PAMAMs of generation 
5 (PAMAM G5: 28,918 MW) as used in this study are positively charged and have 16 
or 128 of NH2 surface groups, respectively (Figure 5B). 
The high density of surface functional groups on PAMAM dendrimers, which may be 
differently charged, enables the polymers to electrostatically interact with other charged 
surfaces like the plasmalemm of a cell (Figure 7). Commonly, most particles are 
transported and taken up by four major routes:  
1) Paracellular aqueous pathway, e.g. water-soluble agents, 2) passive diffusion, 3) 
carrier mediated, and 4) endocytosis via adsorption, receptor mediation or fluid phase. 
Most likely, PAMAM dendrimers are transported by routes 1) and 4) [35-38]. 
 The microvascular endothelium contains highly polar glycosaminoglycans (GAGs) on 
the surface [39]. The GAGs are classified by four groups, as heparin/heparan sulfate 
(HSGAGs), chondroitin/dermatan sulfate (CSGAGs), keratan sulfate and hyaluronic 
acid [40]. The heparin contain the highest negative charge density within GAGs. 
Therefore, the observed extravasation of cationic PAMAM dendrimers molecules may 
also be a function of the electrostatic interactions between the polymers and the 
negatively charged endothelium as in Figure 7 [38]. 
 
 
 
 
 
Introduction 
 16  
 
 
 
 
 
 
 
 
 
Figure 7 | Schematic representation of cellular uptake of PAMAM dendrimer. The electrostatic 
interactions between the PAMAM dendrimer (cationic dendrimers; positive charged -NH2 surface) and 
the negatively charged endothelium. (Modified from Adamson RH et al., J Physiol. 1992 [36, 38]). 
1.4．Phage display 
In addition to utilization of nanoparticles to alter the negatively charged surface of the 
virus capsid, selective targeting can be achieved by peptides binding with high affinity 
to a specific cell-type. We attempted to select endothelial-targeted peptides via phage 
display and biopanning in endothelial cells. 
The phage display method is an efficient tool for affinity selection of target-specific 
peptides [45]. This technology was discovered by George P. Smith in 1985 [41], when 
he demonstrated that foreign DNA fragments inserted into filamentous phages (= 
bacteriophages = a virus that infects and replicates only within a bacterium) are 
displayed as fusion proteins with a random sequence. 
By selecting and sequencing the motives, protein-peptide, protein-protein, and 
protein-DNA interactions can be distinguished. The most common bacteriophages used 
in phage display are filamentous bacteriophage (M13 [25] and fd) and lytic phage (T4 
and T7 [26]), shown as in Figure 8. 
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Figure 8 | Structure of bacteriopahge. A filamentous M13 phage (A) and a lytic T7 phage (B). 
(Adapted from Keisuke Fukunaga et al., Journal of Nucleic Acids 2012 [45]). 
The phage display technology allows for identification of specific interactions between 
randomized phage library peptides on the phage and target proteins, peptides, or other 
molecules [24]. The M13 CX7C phage display library system (C; cystein, X7; 7-mer 
random aa) is based on a vector of M13 phage encoding N-terminal library random 
peptide fused to a gp3 coat protein. The gp3 plays a critical role for phage infection, 
since randomized 7-mer aa peptides are fused in all five copies of the gp3. Infectivity of 
the M13 phage can be significantly affected by a random sequence of the displaying 
peptides. Amplification efficiency of the each selected-M13 phage clone is determined 
by a combination of the infection and secretion rates. A M13 phage library displaying 
CX7C random peptides was screened to enrich phage that selectively bind to target, as 
cells or other molecules shown as in Figure 9. 
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Figure 9 | Procedural of biopanning by phage-display library. The sequence of events that are 
followed in phage display screening to identify polypeptides that bind with high affinity to desired target 
protein or DNA sequence. A typical procedure of the biopanning. 1) binding, 2) washing, 3) eluting of the 
selected phage, 4) amplification of the phage library subset, which bound to the bait, 5) repeating 3-4 
times (rounds; 1 to 4), and analysis of bound phages. (Adapted from Keisuke Fukunaga et al., Journal of 
Nucleic Acids 2012 [45]). 
1.5．Aim of study 
In this study, we aim at retargeting an AAV2/9 virus strain towards endothelial 
transduction. Since all AAV strains have a low transduction efficacy in endothelium 
(Figure 10-a), we utilized surface modifications of the virus capsid to achieve 
endothelial retargeting. We used a three-step strategy to achieve this aim.  
1. First, we tested the combination of AAV2/9 and two cationic PAMAM 
dendrimer (G2 and G5) for endothelial transduction in vivo (figure 10-b). 
2. Secondly, we identified endothelial targeting peptide motifs of 7 amino-acid 
length, by M13 phage-display technology. 
3. Thirdly, we linked the endothelial targeting peptide to PAMAMs for targeting 
endothelial cells in vivo (figure 10-c). 
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Figure 10 | Design of gene delivery system by surface modified AAVs by different type of PAMAM 
dendrimers. a, AAV2/9CMV-Cre virus have a tropism in heart. b, Cationic PAMAM dendrimer (G2 or 
G5) coated AAV2/9CMV-Cre virus. c, AAV2/9CMV-Cre/PAMAM G2-PEG linker-Endo peptide; 
Endothelial cell target motives (P1 or P3) are displayed on PAMAM surface (PEG linker pre-conjugated 
G2 PAMAM) and thereafter coated to AAV2/9CMV-Cre virus. 
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2. MATERIALS AND METHODS 
2.1.  Materials 
2.1.1. Chemicals, solutions and enzymes 
Product Company 
Acetonitril Roth GmbH, Lübeck, Germany 
Agarose Life tech. GmbH, Darmstadt , Germany 
Ampicillin Sigma-Aldrich GmbH, Munich, Germany 
APS Merck, Darmstadt, Germany 
Bacto-agar BD GmbH, Heidelberg, Germany 
Bacto-tryptone BD GmbH, Heidelberg, Germany 
Bovine Serum Albumine (BSA) Sigma-Aldrich GmbH, Munich, Germany 
Calcium Chloride Sigma-Aldrich GmbH, Munich, Germany 
Claycomb medium Sigma-Aldrich GmbH, Munich, Germany 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich GmbH, Munich, Germany 
DMEM Invitrogen GmbH, Darmstadt, Germany 
DNA Ladder 50 bp NEB GmbH, Frankfurt, Germany 
DNA Ladder 1k bp NEB GmbH, Frankfurt, Germany 
DTT Sigma-Aldrich GmbH, Munich, Germany 
EDTA Invitrogen GmbH, Darmstadt, Germany 
Endothelial medium 200 Invitrogen GmbH, Darmstadt, Germany 
Ethanol Roth GmbH, Lübeck, Germany 
Ethidium Bromide Roth GmbH, Lübeck, Germany 
FCS Invitrogen GmbH, Darmstadt, Germany 
Glycerol Roth GmbH, Lübeck, Germany 
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Glycine Roth GmbH, Lübeck, Germany 
HEPES Sigma-Aldrich GmbH, Munich, Germany 
IPTG Sigma-Aldrich GmbH, Munich, Germany 
Isopropanol Roth GmbH, Lübeck, Germany 
KAPA HiFi DNA polymerase PEQLAB Biotech., Erlangen, Germany 
Macro-prep high S BioRad GmbH, Munich, Germany 
Magnesium Chloride Sigma-Aldrich GmbH, Munich, Germany 
NHS-PEG-OPSS Rapp Polymere GmbH, Tübingen, Germany 
NP-40 Sigma-Aldrich GmbH, Munich, Germany 
Nuclease Free Water (NFW) Promega GmbH, Mannheim, Germany 
O.C.T. compound Sakura Finetek Germany GmbH, Germany 
Opti-MEM Invitrogen GmbH, Darmstadt, Germany 
PAMAM dendrimers (G2 or G5) Dendritic Nanotech. Inc, Michigan, USA 
PEG 8000 Sigma-Aldrich GmbH, Munich, Germany 
Penicillin/Streptomycin Invitrogen GmbH, Darmstadt, Germany 
Peptide (no.1 or no.3) Biosyntan GmbH, Berlin, Germany 
RPMI-1640 medium Sigma-Aldrich GmbH, Munich, Germany 
Sephadex G-25 superfine Sigma-Aldrich GmbH, Munich, Germany 
Skim-milk Roth GmbH, Lübeck, Germany 
Sodium chloride Roth GmbH, Lübeck, Germany 
Sodium Dodecyl Sulfate (SDS) Sigma-Aldrich GmbH, Munich, Germany 
Sodium Phosphate Sigma-Aldrich GmbH, Munich, Germany 
Spectra/Por membranes Spectrum Lab. Inc, Breda, Netherlands 
Sucrose Sigma-Aldrich GmbH, Munich, Germany 
T4 DNA Ligase Invitrogen GmbH, Darmstadt, Germany 
TEMED Sigma-Aldrich GmbH, Munich, Germany 
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Tetracycline Sigma-Aldrich GmbH, Munich, Germany 
TFA Roth GmbH, Lübeck, Germany 
TNBS Sigma-Aldrich GmbH, Munich, Germany 
Tris Sigma-Aldrich GmbH, Munich, Germany 
Triton X 100 Roth GmbH, Lübeck, Germany 
TRIzol  Ambion GmbH, Darmstadt, Germany 
Trypsin-EDTA Invitrogen GmbH, Darmstadt, Germany 
Tween 20 Roth GmbH, Lübeck, Germany 
Vectashield H-1200 Vector Lab. Inc., Burlingame, CA, USA 
X-gal Roth GmbH, Lübeck, Germany 
Yeast extract BD GmbH, Heidelberg, Germany 
The water was used as purified by Milli-Q, Millipore Centrifugal filter units Amicon 
Ultra 0.5ml, 3K and 50K from Millipore GmbH (Darmstadt, Germany). All other 
chemicals were bought from Sigma-Aldrich (Munich, Germany), Invitrogen GmbH 
(Darmstadt, Germany) or Roth GmbH (Karlsruhe, Germany). 
2.1.2. Standard kits 
Product Company 
DNeasy Kit Roche Diagnostics GmbH, Penzberg, Germany 
EndoFree Plasmid Kits Macherey-Nagel GmbH, Düren, Germany 
Gel Extraction Kit Macherey-Nagel GmbH, Düren, Germany 
KAPA Mouse genotyping kit PEQLAB Biotech., Erlangen, Germany 
PCR Purification Kit Macherey-Nagel GmbH, Düren, Germany 
Ph.D. CX7Cphage display library NEB GmbH, Frankfurt, Germany 
Reverse transcription system kit Promega GmbH, Mannheim, Germany 
SYBR Green kit BioRad GmbH, Munich, Germany 
TMB Substrate Kit Thermo GmbH., Bonn, Germany 
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2.1.3. Plasmids 
1. pAAV-CMV-eGFP: EGFP cDNA controlled by the human cytomegalovirus (CMV) 
promoter with Ampicillin resistance. 
2. pAAV-CMV-Cre: Cre cDNA controlled by the human cytomegalovirus (CMV) 
promoter with Ampicillin resistance. 
3. pAdΔF6: PolyFlo®Purified Plasmid pAdΔF6 (P.O. Number 03032012 Lot# C30JA) 
from Puresyn Inc. (Malvern, PA) [16, 17]. 
4. pVP2: AAV based helper plasmid containing the AAV2 Rep and Cap open reading 
frame (ORF) with Ampicillin resistance [20]. 
5. pVP2/6: AAV based helper plasmid containing the AAV2/6 Rep and Cap open 
reading frame (ORF) with Ampicillin resistance. 
6. pVP2/9: AAV based helper plasmid containing the AAV2/9 Rep and Cap open 
reading frame (ORF) with Ampicillin resistance [16, 17]. 
7. pVP2/9Endo: AAV based helper plasmid containing the AAV2/9Endo, Endothelial 
cell target peptide (SLRSPPS) displayed on virion, Rep and Cap open reading 
frame (ORF) with Ampicillin resistance [24]. 
8. pAAV-CMV-S1FG: S1FG cDNA controlled by the human cytomegalovirus (CMV) 
promoter with Ampicillin resistance [55]. 
2.1.4. Primers 
M13 phage PCR primer (forward; 5’- TTA TTC GCA ATT CCT TTA GTG G -3’, 
reverse; 5’- CCC TCA TAG TTA GCG TAA CG -3’All primers have been purchased 
from MVG (Ebersberg, Germany). 
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2.1.5. Antibodies 
Name Immunogen Manufacturer 
CD31 PerCP human eBioscience 
Troponin I Alexa647 human BD Biosciences 
CD45 eFluor450 mouse eBioscience 
CD144 eFluor660 mouse eBioscience 
IgG2a K PerCP rat eBioscience 
M13-pIII M13 coat protein III NEB GmbH 
M13-pVIII M13 coat protein VIII Abcam plc 
 
2.1.6. Bacteria strain 
ER2738: The host cell of M13phage. 
DH5α:   The host cell of viral vectors for transformation. 
2.1.7. Cell lines 
bEnd3:   Mouse brain endothelial cell line [16]. 
HEK293: Human embryonic kidney cells [17]. 
HL-1:   Mouse cardiomyocyte. 
HMEC:  Human microvascular cells. 
HUVEC:  Human umbilical vein endothelial cells. 
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2.2. Methods 
2.2.1. Viral vectors 
All vectors were designed to express transgenes or reportergenes (Cre reporter genes) 
under the control of two promoters. The pAAV-CMV-eGFP and pAAV-CMV-Cre 
vectors carry a cytomegalovirus (CMV) enhancer promoter. The constructed plasmids 
(pAAV-CMV-eGFP and pAAV-CMV-Cre), contain 5’- Inverted terminal repeats (ITR), 
a CMV promoter, a transgene (eGFP or Cre), a posttranscriptional regulatory element 
(WPRE), a bovine growth hormone polyadenylation signal (bGHpA), 3’- ITR, a region 
for resistance to the antibiotic Ampicillin (Amp) Figure 11-A. The viral vector plasmids 
were provided by James Wilson, University of Pennsylvania, Philadelphia, USA and 
Oliver J. Müller, University of Heidelberg, Germany. 
2.2.2. Recombinant AAV production 
All production of recombinant AAV was performed using a triple plasmid transfection 
method in principle as described [20]. Briefly, the triple plasmids were an adenovirus 
(Ad) helper plasmid (pAdΔF6), a chimeric trans plasmid containing the AAV2 rep gene 
fused to the capsid gene of the AAV serotype of interest (crosspackaging of pseudotyped 
vectors), and a ITRs-positive rAAV vector plasmid. AAVs were produced with triple the 
pAdΔF6 as Ad helper plasmid. rAAV2-CMV-eGFP virus was produced by 
cotransfection of U293 cells with pAAV-CMV-eGFP and pDG (R484E/R585E) 
containing mutations of two amino acids involved in heparin binding of AAV2 
(R484E/R585E) [21]. rAAV2/6-CMV-eGFP virus used pAAV-CMV-eGFP and pDP6. 
The rAAV2/9-CMV-eGFP and rAAV2/9-CMV-Cre virus used each a pAAV-CMV-eGFP 
or pAAV-CMV-Cre with pDP9. Furthermore, the cross packaging of rAAV2/9Endo-Cre 
virus pseudotyped vector was accomplished with pAAV-CMV-Cre and Endo endothelial 
cell targeting peptide (SLRSPPS) inserted on the surface of A589 of AAV9 capsid 
(p5E18-VD-2/9- SLRSPPS) [24]. After 2-3 days, cells were harvested and viruses were 
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purified using standard cesium sedimentation as previously described [22]. The titer of 
rAAVs viral particle was determined using real-time PCR against the untranslated 
region of the DNA encoded transcript in each AAV vectors. The bGHpA primer 
sequences were forward 5′-TCT AGT TGC CAG CCA TCT GTT GT-3′, and reverse 
5′-TGG GAG TGG CAC CTT CA-3′, Cre primer sequences were forward 5’- AGA 
GGA AAG TCT CCA ACC TG -3’, reverse 5′- ACA CAG ACA GGA GCA TCT TC -3’, 
and eGFP primer sequences were forward 5’- GCC ACA ACG TCT ATA TCA TGG -3’, 
reverse 5′- GGT GTT CTG CTG GTA GTG GT -3’. Real-time PCR was performed 
using SYBR Green for 40 cycles (30 seconds at 95°C, 30 seconds at 58°C, 30 seconds 
at 72°C) by an iQ-Cycler (Bio-Rad, Germany). Cross packaging constructs of 
pseudotyped vectors were provided by Oliver J. Müller, University of Heidelberg, 
Heidelberg, Germany [25]. 
2.2.3. Coating of AAVs with PAMAM dendrimer 
The complexes of rAAVs and nanoparticles (PAMAM G2, PAMAM G5), at times 
carrying endothelial targeting peptides P1 and P3 (PAMAM G2 P1, and PAMAM 
G2-P3) were formed by diluting indicated amounts of AAVs in Opti-MEM (Invitrogen, 
Germany). Viral particles were added to the PAMAM diluted solution, immediately 
mixed by gentle aspiration with the pipet tip and allowed to incubate for at RT/30 min 
before further use, as in Figure 11-B. 
2.2.4. Panning 
In this study we use a phage peptide library Ph.D. CX7C M13KE kit. 2.0E+11 plaque 
forming units (pfu) of the phage library was incubated with 1 ml of 1% BSA/DMEM in 
1.0E+07 cells/tube of the HMEC or HUVEC cells and incubated for 120 min at 4°C 
with gently rolling. After washing 5 times with TBST (TBS/0.1% Tween 20) and 
spinning down at RT/1200 rpm/5 min, bound phages were eluted with a 1 ml of 0.2M 
Glycine-HCl (pH 2.2)/1 mg/ml BSA by centrifugation at 4°C/13000 rpm/5 min. The 
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supernatant of elute was neutralized with a 200 µl of Tris-HCl (pH 8.0). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11 | Construction of gene delivery viral vector and modifications by PAMAM with or 
without peptide linkage. A, pAAV-CMV-eGFP vector (upper part) and pAAV-CMV-Cre vector (lower 
part). B, PAMAM dendrimers (G2, G2P1, G2P3, or G5) coated to AAV (rAAV2, rAAV2/6, rAAV2/9 or 
rAAV2/9Endo) at RT/30 min. 
2.2.5. Amplification of selected phage clones 
1 ml of selected phage eluate was incubated with 20 ml of an E. coli ER2738 bacteria 
suspension (A600 nm 0.5) by vigorous shaking at 37°C/4.5 hr in 250 ml volume. The 
amplified phage was purified according to the method in principle as described [27, 28]. 
Briefly, recovered phages were centrifuged at 4°C/13000 rpm/20 min. Then, the upper 
80% of supernatant were transferred to a fresh tube with 1/6 volume of 20% PEG/2.5M 
NaCl and incubated overnight at 4°C. Thereafter, the phage was pelleted by spinning 
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down at 4°C/13000 rpm/15 min and the supernatant was discarded. The phage pellet 
was completely resuspend with 1 ml of TBS by gently rocking overnight at 4°C. 
Residual pellets were spun down at 4°C/13000 rpm/20 min and the supernatant was 
purified by syringe filter with 0.45 µm (Life Sciences, Germany). Each round of eluted 
solutions was used for determination of phage titration by plaque assay [26]. The 
amplified phage was used as input for the next round and the phage titration used as 
output data. 
2.2.6. Direct phage PCR and sequencing 
10 µl of phage elutes (2 and 3 rounds) were incubated overnight with 300 µl of an E. 
coli ER2738 bacteria suspension (A600 nm OD 0.5) and 3 ml of prewarmed TOP-agar 
medium (10 g Bacto-Tryptone, 5 g yeast extract, 5 g NaCl, and 7 g Bacto-agar per liter) 
onto a LB/IPTG/X-gal plates (1l LB medium, 15 g/l agar, 0.05 g of IPTG, and 0.04 g of 
X-gal per liter). Each of 488 single blue (positive) plaques were random selected and 
amplified with 2 ml of an E. coli ER2738 bacteria suspension (A600 nm OD 0.5) by 
vigorous shaking at 37°C/4.5 hr. Each of purified plaques (488 single positive plagues) 
were reselected by direct PCR. The direct PCR enrichment was performed using DNA 
polymerase for 35 cycles by an iQ-Cycler. Then, 169 phage (positive of direct PCR 
products) were selected by gel electrophoresis. 58 phage DNA sequences were 
identified by sequencing analysis, and finally 10 phage DNA sequences were selected. 
The M13 phage primer sequences were forward 5’- TTA TTC GCA ATT CCT TTA 
GTG G -3’, reverse 5’- CCC TCA TAG TTA GCG TAA CG -3’. The direct PCR 
enrichment was performed using KAPA HiFi DNA polymerase (peqlab, Germany) for 
35 cycles with the following cycling parameters: 3 minutes at 98°C; 35 cycles of 15 
seconds at 98°C, 30 seconds at 53°C, 30 seconds at 72°C; 30 seconds at 72°C by an 
iQ-Cycler (Bio-Rad, Germany). Thereafter PCR products were separated by DNA gel 
electrophoresis compact XS/S (Biometra, Germany). The sequences of the PCR 
products (selected phage DNA) were identified by MWG (Eurofins MWG Operon, 
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Germany). 
2.2.7. Phage ELISA 
10,000 cells/well of HUVEC, and HMEC cells were incubated in a micro 96-well plate 
(Nunc, Germany) overnight at 37°C in 5% CO2. The cell plates were washed with 1x 
phosphate buffered saline (PBS) and fixed with 4% PFA at RT/15 min. Thereafter they 
were washed and blocked at RT for 30 min with 100 µl/well of 2% skim-milk in 1x 
TBST (as blocking buffer). The blocking buffer was removed and individual 10 
amplified phage clones were incubated at RT for 60 min with in endothelial cell 
(HUVEC or HMEC). 50 µl/well of 1:200 HRP-conjugated M13 PVIII antibody were 
added in 2% skim-milk in 1x TBST (as primary antibody solution) and incubate 
overnight at 4°C. Plates were washed 5 times with 100 µl/well of 1x TBST. 100μL/well 
of TMB Substrate (Thermo Fisher Scientific, Germany) were added and incubated at RT 
for 15 min. After adding 100μL/well of TMB Stop Solution, the absorbance at 450nm 
(A450) was analyzed. 
2.2.8. Nanoparticle synthesis 
The PAMAM G2 dendrimer (Figure 12-A) and PAMAM G5 dendrimer (Figure 12-B) 
were synthesized by Dendritic Nanotech. Inc, Michigan, USA. The conjugation of a 
PAMAM G2 dendrimer, a NHS-PEG-OPSS linker and endothelial cell specific 
transduction peptides (P1 or P3) was performed according to [29]. Briefly, 1 μmol of G2 
(MW = 3,284 Da) was incubated with 4 μmol of NHS-PEG-OPSS (2 kDa) dissolved in 
DMSO at 37°C/3 hr. The reaction mixtures were loaded on a cation-exchange column 
(Macro-Prep High S; BioRad) and fractioned with a salt gradient from 0.6 to 3 M NaCl 
in 20 mM HEPES (pH 7.4) solution. Thereafter, the product was filterated by centrifuge 
filter devices (Amicon Ultra 3K) and the G2 content of the conjugate was determined by 
TNBS assay. For G2P1 (Figure 12-C) and G2P3 (Figure 12-D) synthesis, 1.98 μmol of 
peptides in 75 μl of 30% acetonitrile, 70% H2O, 0.1% TFA (trifluoroacetic acid) 
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solution and 0.79 μmol of G2 with PEG-OPSS linker in 3.6 ml of HBS solution were 
mixed and incubated at room temperature. The mixtures were loaded on a 
cation-exchange column with varying salt gradients from 0.6 to 3 M NaCl in 20 mM 
HEPES including 10% acetonitrile (pH 7.4) solution. Thereafter, the product was 
filtered by a centrifuge filter devices (Amicon Ultra 50K and 3K) and the G2 content of 
the conjugate was determined by TNBS assay. The amount of P1 or P3 was calculated 
via the extinction coefficient at 280 nm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12 | Cationic PAMAM dendrimers & surface modified PAMAM dendrimers. A, PAMAM G2 
is a cationic (16 of NH2) generation 2 PAMAM dendrimer. B, PAMAM G5 is a cationic (128 of NH2) 
generation 5 PAMAM dendrimer, C, PAMAM G2P1 is surface modified, adding P1 (CSLRSPPS) with 
PEG linker conjugated on the surface, PAMAM G2 dendrimer. D, PAMAM G2P3 is surface modified, 
adding P3 (CNNSGMRN) with PEG linker conjugated on the surface, PAMAM G2 dendrimer. 
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2.2.9. Cell culture 
For in vitro studies, human microvascular endothelial cells (HMEC), mouse brain 
endothelial cell line (bEnd3), and human embryonic kidney 293 cells (HEK293) were 
cultured in Dulbecco’s modified Eagle’s medium (DMEM). Mouse cardiomyocyte 
(HL-1) were cultured in Claycomb medium, 0.1 mM Norepinephrine. Human umbilical 
vein endothelial cells (HUVEC) were cultured in endothelial medium 200. All cell 
culture medias were supplemented with 10% fetal calf serum (FCS), 1 % 
penicillin-streptomycin solution (100 units/ml penicillin, 100 μg/mL streptomycin), and 
1% L-alanine-L-glutamine (200 mM) at 37°C in 5% CO2. 
2.2.10. Animals 
dTomato mice care and all experimental procedures were performed in to the Guide for 
the Care and Use of Laboratory Animals published by the NIH (NIH publication no. 
85-23, revised 1996), and were approved by the Bavarian Animal Care and Use 
Committee (AZ 55.2-1-54-2531-130-8 and 35-12). All animal experiments were 
conducted at the Walter Brendel Centre of Experimental Medicine. 
2.2.11. ROSA mT/mG mice (tdTomato mice) 
The Cre/loxP system has been widely used for site-specific mutagenesis in mice [3, 46]. 
The Cre recombination activity at specific sites, called lox sites, is instrumental for 
temporal and spatial resolution of the recombination event. The ROSA mT/mG mouse 
strain (B6.129(Cg)–Gt(ROSA)26Sortm4 (ACTB-tdTomato,-EGFP)Luo/J, (The Jackson 
Laboratory, www.jax.org) is a double color fluorescent Cre reporter mouse strain that 
expresses cell membrane-targeted red fluorescence, tandem dimer Tomato (mT) in its 
native state prior to Cre recombinase exposure. In contrast, cell membrane-targeted 
green fluorescent protein (mG) is expressed after Cre-mediated activation of mG, and 
excision of mT as shown in Figure 13 A-C. 
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Figure 13 | Tomato reporter gene mice, mT/mG mutation mice; Gt(ROSA)26Sor. A, Tomato mice are 
characterized by a mT/mG combined in the ROSA locus as displayed in this map. Mice homozygous for 
this mT/mG mutation are viable and fertile. These mice possess loxP sites on either side of a 
membrane-targeted tdTomato (mT) cassette and express strong red fluorescence in all tissues. Tail or 
whole body epi-fluorescence is sufficient to identify mT/mG homozygotes. When bred to Cre 
recombinase expressing mice, the resulting offspring have the mT cassette deleted in the cre expressing 
tissues, allowing expression of the membrane-targeted EGFP (mG) cassette located just downstream. B, 
The phenotype of tomato mice. C, An example of tomato mice after Cre gene transduction. The Cre gene 
mediated mT expression change to mG compared to the mock transfected heart. (Figure A is adaptied 
from Muzumdar et al., Genesis 2007 [3]). 
2.2.12. Genotyping of dTomato mice 
Offspring from matings of a heterozygote Gt (ROSA) 26Sor mouse and a heterozygote 
Gt (ROSA) 26Sor mouse were biopsied at weaning age, and total DNA was prepared 
from the mice tail clip (approx 2 mm) by manual DNA isolation, incubated with 100 μl 
of solution A (25 mM NaOH/0.2 mM EDTA) during 60 min 95°C and vortexed briefly 
with 100 μl of solution B (40 mM Tris-HCl). Thereafter, the mixture was centrifuged at 
2000 rpm for 10 min, and 100 μl of supernatant were removed and used as 1 μl per 25 
μl PCR reaction. The total DNA was analyzed by PCR for the presence of the respective 
transgenes. Primers (wild type for 5′- CTC TGC TGC CTC CTG GCT TCT -3′, wild 
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type rev 5′- CGA GGC GGA TCA CAA GCA ATA -3′, and mutant type rev 5′- TCA 
ATG GGC GGG GGT CGT T -3′) were used for the Gt (ROSA) 26Sor allele PCR. The 
direct PCR enrichment was performed using KAPA HiFi DNA polymerase (peqlab, 
Germany) for 35 cycles with the following cycling parameters: 3 minutes at 98°C; 35 
cycles of 15 seconds at 98°C, 30 seconds at 53°C, 30 seconds at 72°C; 30 seconds at 
72°C by an iQ-Cycler. Thereafter, PCR products were separated by DNA gel 
electrophoresis compact XS/S. The resulting PCR products were mutant type (250 bp), 
wild type (330 bp), and heterozygote type (250 bp and 330 bp) in size. 
2.2.13. Transduction efficiency test in vitro 
Surface modified PAMAM dendrimers coated rAAV transductions were performed 
using HEK293, HL1, bEnd3 and HMEC cell lines with 24hr, 48hr, and 72hr incubation 
time. The PAMAM dendrimer (G2, G2P1, G2P3 or G5) coating doses ranged from 50 
to 800 ng per well, rAAV vector (AAV2-eGFP, AAV2/6-eGFP, AAV2/9-eGFP, 
AAV2/9-Cre, AAV2/9Endo-Cre, as in Figure 14-A & -B) dose were 1.0E+05 virus 
particles per cell or 1.0E+06 virus particles per cell. 
2.2.14. Transduction efficiency test in vivo 
The dtTomato reporter mouse carries a RFP (red) fluorescing reportergene, which upon 
Cre activity switches to GFP (green). Mice of this strain were injected intravenously 
(i.v.) 2.5E+12 virus particles coated with 45 ng or 90 ng of surface modified dendrimers 
(G2, G2P1, G2P3 or G5) or AAV2/9Endo coated with the same amount of cationic 
surface dendrimers (G2 or G5). Successful pCMV-Cre gene transduction of tdTomato 
mouse organs (heart, liver, lung, kidney, spleen, brain, upper limb, and lower limb) was 
analyzed 21 days after viral injection. In this study experimental groups consist of 
AAV2Cre, AAV2/6Cre, AAV2/9Cre, AAV2/9Endo-Cre [24], AAV2/9Cre/G2, 
AAV2/9Cre/G5, AAV2/9Endo-Cre/G2, AAV2/9Endo-Cre/G5, AAV2/9Cre/G2P1, and 
AAV2/9Cre/G2P3. 
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Figure 14 | Gene transduction by surface modified PAMAM coated AAVs in vitro and in vivo. A, In 
vitro transduction test of PAMAM coated AAV encoding for CMV-eGFP. G2 and G5 coated AAV2, 
AAV2/6, and AAV2/9 were applied to human embryonic kidney 293 cells (HEK 293), human 
microvascular endothelial cells (HMEC), and AT-1 mouse atrial cardiomyocyte tumor lineage cells (HL-1) 
during 24 hr to 72 hr. B, In addition, the AAV2/9 Endo displaying endothelial targeting peptide 1 (P1) 
directly on the capsid was coated with G5 in vitro. C, The surface modified PAMAM coated AAV2/9 
CMV-Cre or AAV2/9Endo CMV-Cre are applied by tail vein injection into tdTomato mice. After 3 weeks, 
the mice tissues (heart, liver, lung, kidney, spleen, brain, upper limb and lower limb) are harvested for 
transduction analysis. 
2.2.15. Tissue processing 
The tomato mouse organs were removed and fixed for 4 hours by cold 4% PFA in 0.1 M 
PBS, pH7.4. Then fixed mouse tissues were incubated in 25% sucrose solution at 4°C 
overnight followed by O.C.T. compound (Tissue-Tek, Sakura) for 20 min and stored at - 
80°C until sectioned. Frozen whole organs were cut into 5 micron sections using by 
freezing cryotome (Leica, Germany). For each organ, approximately 30 sections were 
analyzed (5 to 10 slides per group). The sections were examined using by laser-scanning 
confocal microscope system LSM 510 (Leica, Germany) as in Figure 15. 
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Figure 15 | Identification of Cre expression in vivo. a, The Cre gene expressed (green) in endothelial 
cell. b-e, Cre positive expression in endothelium of muscular artery. f-i, positive expression of 
cardiomyocyte in near muscular artery area. j-m, Cre negative expression of muscular artery. DAPI; 
nuclear counterstain, GFP; Cre positive expression, RFP; dtomato gene expression, merge; GFP with RFP. 
Scale Bar; 20 µm. 
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2.2.16. Mouse heart dissociation 
Whole hearts of dTomato mice were washed 3 times in 0.9% NaCl and dissociated into 
single cell suspension by digestion in Collagenase II solution (1mg/ml PBS, Gibco) 
with DNase (50 µg/ml + 3mM MgCl2 3mM), and incubated at 37°C. Detached cells 
were resuspended in PBS/2% FCS and kept on ice with gentle agitation until staining. 
2.2.17. Flow cytometry analysis 
Whole hearts cell-suspensions were stained in ice-cold PBS containing 1% FCS using 
the following surface antibody cocktail. Antibodies against cell-surface markers (human 
CD31, mouse CD45, and mouse CD144) or against internal cell markers (human 
cardiac Troponin I) were incubated for 30 min. Cells were washed, resuspended in 
FACS staining buffer, processed using the Gallios Flow Cytometer, and analyzed using 
FlowJo X software (Beckman Coulter). Endothelial cell (CD31+, CD45-) and 
cardiomyocytes (Troponin I+) sorting gates were set according to unstained control, 
isotype control (rat IgG2a K) and single staining control. 
2.2.18. Whole-mount preparation of the cremaster muscle 
C57Bl/6 mice were anesthesized and placed on a heating pad to maintain body 
temperature. Intravital microscopy of leukocyte adhesion in the cremaster muscle 
preparation was performed by surgically preparation [54]. Briefly, after incision of the 
scrotum of the C57Bl/6 mouse, cremaster muscle was exteriorized and opened through 
a longitudinal incision. Thereafter, live cremaster images were recorded by intravital 
microscopy. The intravital microscopy was conducted on a BX 51 WI microscope 
(Olympus, Munich, Germany) equipped with a charge-coupled device camera (KAPPA 
CF8 HS) and a saline immersion objective (Olympus MplanFI/RI; 0.8 numerical 
aperture). The post-capillary venules were recorded at least 1 min and up to 3 min. 
Leukocyte adhesion, such as defined as non-moving cells or displacement less than one 
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cell diameter during 60 seconds, was analyzed by number of adherent cells per square 
millimeter. Blood flow velocity was measured by a dual-slit photodiode live measuring 
device (Circusoft Instrumentation, Hockessin, DE) and blood counts were determined 
through Idexx Procyte Dx hematology analyzer (Idexx Europe, Hoofddorp, 
Netherlands). 
2.2.19. Statistics 
Data are given as mean ± SD. p < 0.05 was considered statistically significant. All data 
were assessed using the Student’s t-test was performed (http://studentsttest.com) or 
ANOVA followed by Student-Newman-Keuls-test for more 3 groups. The gradations 
were used in this analysis to illustrate the magnitude of significance (*: p <0.05, **: p 
<0.005, ***: p <0.0005). 
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3. RESULTS 
3.1. Optimization of Transduction efficiency of AAV/PAMAM 
complexes in vitro 
For the in vitro optimization of AAV vectors using PAMAM dendrimers, complexes of 
AAV2/9-CMV-eGFP/G5 were first characterized in cell culture (Figure 16). A human 
embryonic kidney cell line (HEK 293; Figure 16-A) or human microvascular 
endothelial cells (HMECs; Figure 16-B) were transduced with two doses of 
AAV2/9-CMV-GFP virus particles (1.0E+05 vp/cell or 1.0E+06 vp/cell) either alone or 
coated with 3, 8, 12, or 16 pg/cell of PAMAM G5, a 48 h incubation period at 37°C. 
Cell images were analyzed by fluorescence microscopy (Zeiss) with image J v1.47 
(http://rsb.info.nih.gov/ij/index.html). As shown, optional conditions for transduction (> 
60%) were the 16 pg/cell of PAMAM G5 coating 1.0E+06 vp/cell AAV2/9-CMV-eGFP 
(Figure 16-C & -D). 
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Figure 16 | Transduction efficiency characterization of AAV2/9-CMV-eGFP and AAV2/9- 
CMV-eGFP/PAMAM complexes in vitro. HEK 293 (A & C) or HMEC (B & D) were transduced with 
two doses of AAV2/9-CMV-GFP virus particles, as shown (open bars; 1.0E+05 vp/cell, black bars; 
1.0E+06 vp/cell), either alone or coated with 3, 8, 12, or 16 pg/cell of PAMAM G5. Values represent the 
mean ± SD (n=3). 
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3.2. Transduction efficiency by different serotypes of AAVs 
Transduction efficacies of wildtype AAV2-CMV-eGFP or AAV2/6-CMV-eGFP were 
altered by coating with PAMAM G5 in vitro (Figure 17). HMECs or murine 
cardiomyocytic cell line HL-1 cells were transduced with AAV2-CMV-GFP (Figure 
17-A & -C) or AAV2/6-CMV-GFP (Figure 17-B & -D) virus particles (1.0E+06 vp/cell), 
either alone or coated with 2, 6, or 10 pg/cell of PAMAM G5. Thereafter, transduction 
efficacy was analyzed by fluorescence microscopy and quantified. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17 | AAV2 and AAV2/6 virus strains were incubated at 37°C/72 h with PAMAM G5. HMECs 
(A & B) or cardiomyocytic HL-1 cells (C & D) were transduced with AAV2-CMV-GFP (A & C) or 
AAV2/6-CMV-GFP (B & D) virus particles (1.0E+06 vp/cell), either alone (open bars) or coated with 2, 
6, or 10 pg/cell of PAMAM G5 (black bars) after a 72 h incubation period at 37°C. Transduction 
efficiency of G5/AAV complexes were analyzed by fluorescence microscopy and quantified. Values 
represent the mean ± SD (n=3). 
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3.3. Transduction efficacies of G2 and G5 PAMAM dendrimers 
Transduction efficacies of G2 PAMAM versus G5 PAMAM coating were characterized 
in vitro (Figure 18) at 37°C/72 h. Human microvascular endothelial cells (HMECs; 
Figure 18-A), or mouse brain endothelial cell line (bEnd.3 cells; Figure 18-B), were 
transduced with AAV2/6-CMV-eGFP virus particles (1.0E+06 vp/cell), either alone or 
after coating with 2, 4, or 6 pg/cell of PAMAM dendrimers (PAMAM G2 or G5). As a 
result, 6 pg/cell of PAMAM G5 with AAV2/6-CMV-eGFP complexes (38.30 ± 4.21 % 
in HMECs, 39.35 ± 6.63 % in bEnd.3 cells) were more efficient than only 
AAV2/6-CMV-eGFP 11.54 ± 7.19 % in HMEC, 2.34 ± 1.35 % in bEnd.3 cells) in vitro. 
As shown, the most efficient condition of PAMAM/AAV -combinations was the 6 
pg/cell of PAMAM dendrimers (PAMAM G2 or G5). 
 
 
 
 
 
 
 
 
Figure 18 | Comparison of G2 vs G5 PAMAM coated AAV2/6-CMV-GFP in endothelial cells at 
37°C/72 h. HMECs (A; n=3) or bEndo.3 cells (B; n=5) were transduced with AAV2/6-CMV-eGFP virus 
particles (1.0E+06 vp/cell), either alone (open bars) or coated with 2, 4, or 6 pg/cell of PAMAM 
dendrimers (G2: gray bars or G5: black bars). Bars present transduced cells/total cells, M; mock, GFP; 
AAV2/6-CMV-eGFP, GFP/G2; PAMAM G2 coated AAV2/6-CMV-eGFP, GFP/G5; PAMAM G5 coated 
AAV2/6-CMV-eGFP. Values represent the mean ± SD. 
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3.4. Biopanning 
In order to improve the efficacy of PAMAM-mediated transduction and achieve a 
retargeting of the AAV vectors towards endothelial cells, we next selected 
endothelium-affine peptides from a M13 phage library (Figure 19-A1). 2x10
11
 plaque 
forming units (pfu) of the CX7C M13KE phage library were incubated with 1 ml of 1% 
BSA/DMEM in each 1x10
7
 cells/plate of the HMEC or HUVEC cells for 120 min at 
room temperature (RT) (Figure 19-A2). The results of phage selection are shown in 
Figure 19. 
According to our prediction, the eluted solutions from the third round (HUVEC; 
5.3x10
6
 ± 3.3x10
6 
pfu, HMEC; 1.9x10
6
 ± 1.5x10
6
 pfu) were binding with higher affinity 
to endothelial cells as compared to outputs from first (HUVEC; 5.1x10
1
 ± 5.0x10
1
 pfu, 
HMEC; 2.6x10
1
 ± 2.5x10
1
 pfu) and second round (HUVEC; 3.5x10
3
 ± 1.5x10
3
 pfu, 
HMEC; 3.3x10
3
 ± 2.5x10
2
 pfu, cf. Figure 19-B & C). 
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Figure 19 | Panning procedure of motif selection for targeting endothelial cells. A, a CX7C M13KE 
phage library 1) was incubated with a HUVEC or a HMEC at 4’C for 120 min 2). The endothelial cell 
bound phages were selected by rigid washing of non-bound phages 3). Bound phages were eluted 4). The 
eluted phages were amplified in E. coli ER2738 5) and subjected to the next round of selection for up to 
3 rounds (3R) 6). B and C, The phage titers of elutions of each round were measured using plaque assays 
in HUVEC (B) or HMEC (C). Cont; original CX7C M13KE phage library, 1R; first round elution, 2R; 
second rounds elution, 3R; third rounds elution, values represent the mean ± SD (n=3). 
3.5. Direct phage PCR and sequencing 
Each of 488 single blue (positive) plaques were selected from eluted phages on the 
LB/IPTG/X-gal plate (the results of 2 rounds and 3 rounds) and amplified in small 
volume with an E. coli ER2738 bacteria suspension (A600 nm OD 0.5) by vigorous 
shaking at 37°C/4.5 h. After purification, 1 µl of selected phage was analyzed by PCR 
with M13 phage PCR primers (forward; 5’- TTA TTC GCA ATT CCT TTA GTG G -3’, 
reverse; 5’- CCC TCA TAG TTA GCG TAA CG -3’).  
3.6. Phage ELISA 
Individual 10 phage clones (4 phage clones screened in HUVEC and 6 phage clones 
screened in HMEC) were tested for binding to target cells by incubation at RT for 120 
min in endothelial cells (HUVEC or HMECs) and removed of non-bound phage clones. 
The bound phage clones were incubated with HRP-conjugated M13 PVIII antibody at 
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4’C for O/N and analyzed by TMB Substrate for absorbance at 450 nm. U1 to U4 phage 
clones were selected after panning from HUVEC, M1 to M6 phage clones were selected 
after panning from HMEC (Figure 20). U4, M1, M4, and M6 phages bound with high 
affinity to both endothelial cell, but M2 and M3 phages bound only in HMEC.  
 
 
 
 
 
 
 
 
Figure 20 | Selected phages target to endothelial cell by Phage ELISA. Individual 10 phage clones 
were incubated with in HUVEC (open bars) or HMEC (black bars) and analyzed absorbance at 450 nm. 
U1 to U4; phage clones were selected from HUVEC, M1 to M6; phage clones were selected from HMEC. 
Values represent the mean ± SD (n=4). 
3.7.  Identification of predominant motifs 
The graphical sequence logo represents predominant motifs of 10 identified amino acid 
phage sequences. The conserved sequence pattern was generated using WebLogo3 
(Figure 21). As shown, the predominant motif was identified with the first 4 site of 
amino acid sequence N (Asn; Asparagine), N, S (Ser; Serine), G (Gly; Glycine), and last 
one amino acid sequence is also N. The unknown sequences, as fifth and sixth amino 
acid sequence, were decided according to phage ELISA results and alignment analysis 
of the 10 peptide sequences using Clustal W program (Figure S1). The final selected 
two novel endothelium target motifs were peptide no.2; CNNVGGWN and peptide no.3; 
CNNSGMRN (Table 4). 
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Figure 21 | Graphical sequence logo representation of predominant motif. The conserved sequence 
pattern was generated using WebLogo3 (http://weblogo.berkeley.edu/). Hydrophilic amino acid (green 
letters); QNSTCGP, hydrophobic amino acid (red letters); AILMFWYV, positive charged amino acid 
(black letters); RHK, negative charged amino acid (blue letters); DE, X of red letter); hydrophobic amino 
acid and X of black letter; positive charged amino acid. 
 
 
 
 
No. Sequence Homologous Identifications Function Accession no. 
1 CSLRSPPS CSLCSPPS Fibroblast growth factor receptor 3 Cell-surface receptor P22607 
2 CNNVGGWN VGGWN Actin-binding protein IPP Organizing the actin cytoskeleton Q9Y573 
3 CNNSGMRN CNNRGM Stabilin-2 ER* for heparin internalization Q8R4U0 
 
Table 4 | Identification of homologous. Peptides were analyzed using the National Center for 
Biotechnology Information BLAST search against the SWISSPROT database, using the option for short 
nearly exact matches, to identify human proteins with homologous sequences. ER*; Endocytosis 
receptor. 
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3.8. Surface modified nano complexes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22 | Design of surface modified PAMAM dendrimers coated AAV2/9. Endo-Cre/G5 c) or 
Cre/G5 e) coating an AAV2/9Endo-Cre (Endo-Cre) or AAV2/9Cre (Cre) compexed with G5 PAMAM d), 
and Endo-Cre/G2 f) or Cre/G2 h) coating an Endo-Cre or Cre with G2 PAMAM g). Endothelial cell 
target motifs peptide no.1 (P1) i) or peptide no.3 (P3) l), as CX7 peptides, were identified by AAV 
display library a) or M13 phage display library b). Thereafter, they were synthesized and displayed on the 
surface of G2 PAMAMs. Cre/G2P1 k) or Cre/G2P3 n) contribute an AAV2/9Cre with G2P1 j) or G2P3 
m). 
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In this study, we studied two cationic surfaced PAMAM dendrimers, namely G2 
(-(NH2)16; Figure 22-g) or G5 (-(NH2)128; Figure 22-d), and two surface modified 
PAMAM dendrimers, such as G2-PEG linker-P1 (G2P1) or G2-PEG linker-P3 (G2P3) 
for transduction efficiency of cardiomyocyte and endothelial cells in heart. The two 
PAMAM dendrimers with cationic surface were synthesized by Dendritic Nanotech. Inc, 
Michigan, USA, whereas surface modifications of PAMAM dendrimers were performed 
in our lab in cooperation with Manfred Ogris (Pharmazie, LMU). The two endothelium 
target motifs, pentavalent amino acid peptide no.1 (P1) and peptide no.3 (P3), of surface 
modified PAMAM dendrimers were identified either by AAV display library (K. Varadi 
et al., Gene Therapy 2012 [24]) or by the M13 phage display library (Ph.D. CX7C 
M13KE, New England Biolabs, see Methods section), respectively (Figure 22-b). The 
identified P1 (CSLRSPPS-amind; MW: 845.99) and P3 (CNNSGMRN-amind; MW: 
894.98) were synthesized (Figure 22-I & -l) and conjugated to the G2-PEG linker 
(NHS-PEG-OPSS), such as G2P1 (Figure 22-j) or G2P3 (Figure 22-m). 
The pAAV-CMV-Cre plasmid was used in a model of systemic gene transduction (tail 
vein injection of AAV2/9-CMV-Cre virus (Cre)) in dTomato mice. The mice are 
characterized by stop loxP cassettes before mG sites on either side of a 
membrane-targeted dTomato (mT) cassette and default red fluorescence in all tissues. 
When exposed to Cre recombinase, the mT cassette is deleted and expression of the 
membrane-targeted EGFP (mG) cassette is enabled. The surface modified PAMAM 
dendrimers (G2P1 or G2P3) were coated with pAAV2/9-Cre by incubation at 30 min at 
the room temperature, such as Cre/G2P1 (Figure 22-k) or Cre/G2P3 (Figure 22-n). We 
also used endothelial cell targeting peptide no.1 (SLRSPPS) inserted on the surface of 
A589 of AAV9 capsid, termed Endo-Cre (p5E18-VD-2/9-SLRSPPS-Cre). Endo-Cre/G5 
(Figure 22-c) or Endo-Cre/G2 (Figure 22-f) were complexes of AAV2/9Endo-Cre 
(Endo-Cre) with G5 or G2 PAMAMs. Cre/G5 (Figure 22-e) or Cre/G2 (Figure 22-h) 
were complexes of AAV2/9-Cre with G5 or G2. 
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3.9. Transduction efficiency by peptide-modified G2 in vitro 
Transduction efficiency of unmodified PAMAM dendrimers versus surface modified G2 
PAMAMs were characterized after coating AAV2/6-CMV-eGFP and application in 
endothelial cells in vitro (Figure 23). 
5.0E+05 vp/cell of AAV2/6-CMV-eGFP virus particles (low virus dose) were 
transduced without or with 2 pg/cell of each different surface the modified G2 PAMAM 
dendrimers in HMECs at 37°C/72 h (Figure 23-A), and intensity of GFP expression per 
total RFP area was analyzed (Figure 23-B). The transduction efficiency of 
AAV2/6-CMV-eGFP/G2 (AAV/G2; 6.20 ± 3.13 %), AAV2/6-CMV-eGFP/G5 (AAV/G5; 
7.08 ± 4.29 %), AAV2/6-CMV-eGFP/G2P1 (AAV/G2P1; 10.87 ± 6.31 %), and 
AAV2/6-CMV-eGFP/G2P3 (AAV/G2P3; 15.04 ± 5.77 %) was increased compared 
AAV2/6-CMV-eGFP only (AAV; 3.76 ± 1.29 %) in HMECs. As shown below (figure 
23), G2-PEG-P3 (G2P3) coated AAV2/6-CMV-eGFP virus was highly transduced in 
HMECs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23 | Transduction efficiency characterization of peptide modified G2 with 
AAV2/9-CMV-eGFP complexes in endothelial cell. AAV2/6-CMV-eGFP virus particles (5.0E+05 
vp/cell) were transduced with alone or 2 pg/cell of each different surface modified PAMAM dendrimers 
in HMEC at 37°C/72 h. A, Transduced cells signal (green) were indicated by AAV2/6-CMV-eGFP. B, 
Bars present transduced cells/total cells. Values represent the mean ± SD (n=3). 
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3.10. Dose effects of G5 coating to AAV2/9-Cre in dTomato mice 
(in vivo) 
In this study, we focused to arteries (A), (muscular arteries; 250 ± 50 µm, arteriole; 28 ± 
15 µm, and capillaries; 3.3 ± 0.5 µm)[86], of heart or hind limb for several artery 
disease causing (ex, atherosclerosis; a specific type of arteriosclerosis) in vivo model. 
AAV2/9Cre was coated by incubation of 2.0E+12 vp of AAV2/9Cre virus with 45 
µg/mouse or 90 µg/mouse of G5 in 30 min at RT, as Cre/G5-45 or Cre/G5-90. Those 
were administered into the tail vein of dTomato mice (7 ~ 9 month) and the mice were 
sacrificed after injection 3 week (21 days) later (Figure 24).  
In the AAV2/9Cre/G5-90 group, the vector transduced both the cardomyocyte of artery 
(A) area (45.23 ± 7.72 A.U.; Figure 24-A & B) and muscle area (64.98 ± 7.20 A.U.; 
Figure 24-C & D) more efficiently than the AAV2/9Cre group (A area; 20.58 ± 5.84 
A.U., muscle area; 28.78 ± 4.14 A.U.) by intensity (A.U.; arbitrary units) in the 
dTomato heart. The AAV2/9Cre/G5-45 group was significantly higher transduced (A 
area; 28.17 ± 3.14 A.U., muscle area; 45.07 ± 19.70 A.U.) compared to the AAV2/9Cre 
group. Values the mean ± SD (n=1). 
 
 
 
 
 
 
 
 
 
Results 
 50  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24 | Transduction efficacy of G5 in dTomato mice heart. A, Transduction efficacy in the artery. 
GFP; Cre positive expression, RFP; dtomato gene expression, merge; GFP with RFP, enlarge; 3 fold large 
image of white dashed line square box, A; artery (white dashed line), CM; cardiomyocyte, scale bar; 20 
µm. B, Intensity (A.U.; arbitrary units) of GFP expression per total RFP area. C, Gene delivery efficacy 
in the cardiomyocyte of dTomato. GFP; Cre positive expression, scale bar; 20 µm. D, Intensity (A.U.; 
arbitrary units) of GFP expression per total RFP area. Values represent the mean ± SD (n=1). 
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3.11. PAMAM G5 coating of AAV2/9Endo-Cre in vivo 
The cross packaging of AAV2/9Endo-Cre virus was accomplished with 
pAAV-CMV-Cre plasmid and endothelial cell targeting peptide (SLRSPPS) inserted on 
the surface of A589 of AAV9 capsid (p5E18-VD-2/9-SLRSPPS) [24]. 2.0 x 10
12
 vp of 
AAV2/9Endo-Cre virus were coated with 25 µg/mouse or 45 µg/mouse of G5 in 30 min 
at RT, as AAV2/9Endo-Cre/G5-25 or AAV2/9Endo-Cre/G5-45. Those were 
administered into the tail vein of dTomato mice (7 to 9 month) and the mice were 
sacrificed after injection 3 week (21 days) later. The images were analyzed by confocal 
microscopy (LSM 510) with image J v1.47 (Figure 25). 
In the AAV2/9Endo-Cre/G5-45 group, we found a higher transduction of arteries (A) 
(posi; 33.3 %, around; 25.9 %, and nega; 40.7 %) than in the unmodified AAV2/9Cre 
group (posi; 12.5 %, around; 75.0 %, and nega; 12.5 %) or the capsid-modified 
AAV2/9Endo-Cre group (posi; 0.0 %, around; 10.0 %, and nega; 90.0 %). Of note, 
transduction efficacy of AAV2/9Endo-Cre/G5-45 group was reduced in both, the 
arteries area (2.03 ± 4.81 A.U., p-value < 0.0005) (Figure 25-A & C) and the muscle 
area (1.69 ± 2.13 A.U., p-value < 0.0005) (Figure 25-D) compared to the AAV2/9Cre 
group (A area; 59.08 ± 26.15 A.U. muscle area; 154.28 ± 18.13 A.U.). 
The results of AAV2/9Endo-Cre/G5-45 group shown that coating G5 PAMAM can help 
to increase transduction efficacy to targeted cell types according to specific affinities of 
the coated virus type. 
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Figure 25 | Transduction efficacy of AAV2/9Endo-Cre/G5 in dTomato mice heart. A, Transduction 
efficacy in arteries. The white arrows were indicated Cre positive expression (green) of endothelium in 
arteries. GFP; Cre positive expression, RFP; dtomato gene expression, merge; GFP with RFP, enlarge; 3 
fold large image of white dashed line square box, A; arteries (white dashed line), CM; cardiomyocyte, 
Scale Bar; 20 µm. B, demonstration of Cre positive revel (percentage; Cre positive expressed arteries per 
total arteries), as shown in A). posi (black bars), around (gray bars), and nega (strip bars). C, Intensity 
(A.U.; arbitrary units) of GFP expression per total RFP area, as shown in A). Values represent the mean ± 
SD. D, Intensity (A.U.; arbitrary units) of GFP expression per total RFP area in cardiomyocyte. Values 
represent the mean ± SD. 
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3.12. AAV2/9Cre/G2 transduction of dTomato mice in vivo 
The AAV2/9Cre virus particles were coated by incubation with 2.0 x 10
12
 vp of 
AAV2/9Cre virus and 45 µg/mouse of PAMAM dendrimers (G2 or G5) in 30 min at RT, 
as Cre/G2 or Cre/G5. Those vectors were administered into the tail vein of dtomato 
mice and the mice were sacrificed after injection 3 week (21 days) later. The 
transduction efficacy test groups (n=3, per group) were control (PBS), AAV2/9Cre 
alone, AAV2/9Cre/G2 and AAV2/9Cre/G5 in the dTomato heart. The images were 
analyzed by confocal microscopy (LSM 510) with image J v1.47 (Figure 26 & Figure 
S2 - S5). 
AAV2/9Cre/G2 transduced vessels to a similar extent as AAV2/9Cre/G5 (20.42 ± 7.59 % 
vs. 19.74 ± 4.69 %), which was higher than AAV2/9Cre only (9.03 ± 4.76 %). The white 
arrows indicate Cre-positive luminal surface events (= transduced endothelium) of 
arteries. Furthermore, nano-particle coating enhanced parenchymal transduction. e.g., 
AAV2/9Cre/G5 achieved 99.86 ± 39.51 A.U. and AAV2/9Cre/G2 86.30 ± 15.69 A.U. 
compared to the AAV2/9Cre only (39.50 ± 16.00 A.U.) in the dTomato mice mouse 
hearts. 
In summary, nano-particle coating enhances cardiomyocyte transduction in the heart. 
Moreover, G2 PAMAM coating helps to target inner vessel layers, e.g. endothelium, 
more efficiently than G5 PAMAM coating of AAV2/9. 
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Figure 26 | Transduction efficacy of AAV2/9Cre/G2 or AAV2/9Cre/G5 in dTomato heart. A, Gene 
delivery efficacy in the arteries. The white arrows were indicated Cre positive expression (green) in 
endothelium of arteries. GFP; Cre positive expression, RFP; dtomato gene expression, merge; GFP with 
RFP, enlarge; 3 fold large image of white dashed line square box, A; arteries (white dashed line), CM; 
cardiomyocyte, Scale Bar; 20 µm. B, Demonstration of Cre positive revel (percentage; Cre positive 
expressed arteries per total arteries), as shown in A. posi (black bars); Cre positive expression in 
endothelium of arteries, around (gray bars); Cre positive expression of cardiomyocyte in near arteries area, 
nega (strip bars); Cre negative expression. C, Gene delivery efficacy in the cardiomyocyte. GFP; Cre 
positive expression. Scale Bar; 20 µm. D, Intensity (A.U.; arbitrary units) of GFP expression per total 
RFP area, as shown in C). Values represent the mean ± SD (n=3). 
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3.13. Specific endothelial transduction of AAV2/9Endo-Cre/G5 
AAV2/9Endo-Cre virus particles, as modified to display peptide no.1 (CSLRSPPS) on 
the surface of AAV2/9 capsid (Varadi K. et al., Gene Therapy 2012 [24]), were coated 
with 45 µg/mouse of PAMAM dendrimers (G2 or G5). Those were administered into 
the tail vein of dTomato mice and the mice were sacrificed after injection 3 week (21 
days) later. Efficacy of gene delivery was compared between control (PBS), AAV2/9Cre, 
AAV2/9Endo-Cre, AAV2/9Endo-Cre/G2 and AAV2/9Endo-Cre/G5. As shown, 
transduction efficiency of endothelium in arteries of Endo-Cre/G5 group (33.73 ± 
7.26 %) was higher than in the Endo-Cre/G2 group (9.40 ± 10.23 %), and Endo-Cre 
alone group (0.0 ± 0.0 %) as well as the Cre group (9.03 ± 4.76). Furthermore, 
cardiomyocyte transduction efficiency of Endo-Cre groups was reduced (2.87 ± 1.27 
A.U.) compared to the Cre group (158.91 ± 18.96 A.U.) when fluorescence intensity 
was analyzed in the dTomato heart. Additionally, cardiomyocyte transduction 
efficiencies of Endo-Cre/G2, and Endo-Cre/G5 groups were also reduced (Endo-Cre/G2; 
0.37 ± 0.23 A.U., Endo-Cre/G5; 0.32 ± 0.27 A.U.) compared to Endo-Cre group, which, 
however, was already much lower than the Cre group. As the results show, G5 PAMAM 
coating improved endothelium transduction to a significant, extent (Figure 27-A). 
However, Endo groups (Endo alone, Endo-Cre/G2, and Endo-Cre/G5) display reduced 
cardiomyocyte transduction in heart. It seems that the Endo-peptide coating induces 
negative selection of the cardiomyocyte compartment, whereas G2 and G5 increase 
targeting of the endothelium. 
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Figure 27 | Transduction efficacy of AAV2/9Endo-Cre /G2 or AAV2/9Endo-Cre /G5 in dTomato 
heart. A, The white arrows indicate Cre positive expression (green) in endothelium of arteries. GFP; 
Cre positive expression, RFP; dtomato gene expression, merge; GFP with RFP, enlarge; 3 fold large 
image of white dashed line square box, A; arteries (white dashed line), CM; cardiomyocyte, scale bar; 
20 µm. B, Demonstration of Cre positive revel (percentage; Cre positive expressed arteries per total 
arteries), as shown in A. posi (black bars); Cre positive expression in endothelium of arteries, around 
(gray bars); Cre positive expression of cardiomyocyte in near arteries area, nega (strip bars); Cre 
negative expression. C, Transduction efficacy in the cardiomyocyte. GFP; Cre positive expression, 
scale bar; 200 µm. D, Intensity (A.U.; arbitrary units) of GFP expression per total RFP area, as shown 
in C). Values represent the mean ± SD (n=3). 
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3.14. Endothelial-targeted transduction of AAV2/9Cre/G2P3 
AAV2/9Cre virus was modified by linking G2 PAMAM dendrimers with the 
endothelial-affine peptides P1 and P3 attached to a PEG linker complex (see Methods 
2.2.8). Those modified virus particles were administered systemically by tail vein 
injection of dTomato mice, and the mice were sacrificed 21 days later. In the dTomato 
mouse heart, transduction efficacy of arteries in the Cre/G2P3 group (43.87 ± 8.70 %) 
were significantly higher than the Cre/G2P1 group (23.39 ± 5.11 %), the Cre/G2 group 
(20.42 ± 7.59 %) as well as the Cre alone group (9.03 ± 4.76 %). 
Furthermore, transduction efficiency of Cre/G2P1 and Cre/G2P3 groups were higher in 
the cardiomyocyte compartment Cre/G2P1 (180.00 ± 49.46 A.U.) and Cre/G2P3 
(169.64 ± 20.37 A.U.) than in the Cre/G2 group (107.64 ± 38.62 A.U.) in the dTomato 
mouse hearts (Figure 28). 
Moreover, our results show that Cre/G2P3 virus particles transduced endothelium at 
higher rates than all other transduction groups (43.87 ± 8.70 % of the arteries in the 
heart). However, it is difficult to derive microcirculatory endothelial transduction 
efficacies from these morphological studies in mid-size arteries. To independently study 
general endothelial transduction, we conducted FACS analysis of dTomato mouse hearts 
digested 3 weeks after transduction and gated for the endothelial marker PECAM-1 
(Figure 29). Taken together, combining AAV2/9 with nano-coating (PAMAM G2) and 
endothelial targeting peptide P3 dramatically increases vessel transduction of murine 
dTomato hearts. The comparison to P1 (SLRSPPS, cf. Varadi K et al.) indicates a 
tendency towards a stronger effect of P3, without statistical significance (Figure 27). 
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Figure 28 | Transduction efficacy of AAV2/9Cre/G2P1 or AAV2/9Cre/G2P3 in dTomato mice. A, 
Transduction efficacy in the cardiac artery. The white arrows were indicated Cre positive expression 
(green) in endothelium of cardiac artery. GFP; Cre positive expression, RFP; dtomato gene expression, 
merge; GFP with RFP, enlarge; 3 fold large image of white dashed line square box, A; arteries (white 
dashed line), CM; cardiomyocyte, scale bar; 200 µm. B, Demonstration of Cre positive revel 
(percentage; Cre positive expressed arteries per total arteries), as shown in A. posi (black bars); Cre 
positive expression in endothelium of arteries, around (gray bars); Cre positive expression of 
cardiomyocyte in near arteries area, nega (strip bars); Cre negative expression. Values represent the 
mean ± SD (n=3). C, Transduction efficacy in the cardiomyocyte. GFP; Cre positive expression, scale 
bar; 200 µm. D, Intensity (A.U.; arbitrary units) of GFP expression per total RFP area, as shown in C). 
Values represent the mean ± SD (n=3). 
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Figure 29 | Whole heart analysis of dTomato mice by FACS. Mouse whole heart dissociated and 
stained for endothelial cell (PerCP conjugated CD31) after 21 days i.v. injection. Isotype control staining 
was performed with IgG2a K PerCP. GFP+ cells per total endothelial cells (CD31+), as shown main 
groups (PBS, Cre, Cre/G2, Cre/G2P1 or Cre/G2P3). Values represent the mean ± SD (n=3). 
3.15. Functional evidene for endothelial transduction by 
AAV2/9-S1FG/G2P3: an in vivo adhesion assay 
In order to prove that Cre/C2P3 is capable of endothelial transduction, we selected a 
transgene which exerts its function only when represented on the luminal surface of the 
endothelial layer. The fusion protein S1FG is an artificial adhesion molecule based on 
the SDF-1 (CXCL12) and the mucin backbone taken from fractalkine (CX3CL1). A 
GPI-anchor was included to link the fusion protein (Figure 30-A) [55]. We compared 
mice systemically treated with endothelial-targeted Cre/G2P2 with wildtype Cre and 
saline injection (control). As a read out, non-stimulated adhesion of PMN on the 
endothelium (cremaster muscle area) was quantified by intravital microscopy 21 days 
after virus injection. The cremaster venules images were processed by intravital 
microscopy, a BX 51 WI microscope (Olympus, Munich, Germany) equipped with a 
charge-coupled device camera (KAPPA CF8 HS) [54], and analyzed by image J v1.47. 
In this model, the number of adherent neutrophil was more than 5-fold increased in the 
S1FG/G2P3 group compared with non-coated group S1FG-AAV group and control 
group, Figure 30-B & C. 
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Figure 30 | Functionality of the S1FG fusion protein by intravital microscopy. A, A fusion protein 
S1FG combined of SDF-1 1), the mucin domain of CX3CL1 2), and the GPI-anchor 3) [55]. B, S1FG 
enhances adhesion of neutrophil (black dot) in cremaster muscle venules (red box). C, Adhesion of 
neutrophil showed a significant increase with G2P3 coated AAV2/9-S1FG manner. Values represent the 
mean ± SD (n=4; ns: not significant, ***: P<0.0005, ANOVA t test).  
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4. DISCUSSION 
In the last 15 years, various research groups studied endothelial targeted gene delivery 
systems by using screening systems. Several approaches engineered AAV2 vectors by 
expressing phage display peptide libraries on the envelope surface and selecting 
peptides. Whereas Stuart Nicklin and colleagues focused on human endothelial cells in 
vitro (Nicklin SA et al., Mol Ther 2001 [49]), Lorraine Work from the same group 
accomplished improved transduction of lung endothelia in vivo (Work LM et al., Mol 
Ther 2006 [50]), Yong Hong Chen and coworkers improved brain endothelial 
transduction and cerebral disease symptoms (cf. Chen YH et al., Nat Med 2009 [47]) 
and Oliver Müller et al. focused on coronary endothelium (Müller-OJ, Kleinschmidt, 
Trepel-M et al., Nat Biotech 2003 [51]) by displaying peptides on the surface of the 
AAV2 envelope. However, direct proof of virus expression on endothelial cells in vivo 
was not obtained in these earlier studies. 
Since AAV serotype 9 was discovered meanwhile, demonstrating efficient transduction 
of the heart (Zincarelli Carmela et al., Mol Ther 2008 [83]), we focused on this novel 
envelope, however, leaving the genetic elements of AAV2 in place for biosafety (AAV2 
being viewed as not human-pathogenic). 
In the current study, we utilized a novel AAV2/9 virus strain to target primary human 
coronary artery endothelial cells by combining AAV display peptide libraries studies 
with nanoparticle (PAMAM dendrimer) coating and peptide linkage to the dendrimers 
for the first time. 
4.1. Nanoparticle coating 
First, we assessed the role of the chosen biodegradable cationic nanoparticles 
(polyaminoamide = PAMAM dendrimers), consisting of a diaminobutane as core and 
branched polyethylenimine of second or fifth generation (termed G2 or G5). We found 
that coating the AAV2/9 virus capsid with PAMAMs increased transduction of 
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cardiomyocytic and endothelial cell lines alike in vitro (Fig. 17). This increased 
transduction efficacy was found for both, the smaller G2 and the larger, wider branched 
G5 PAMAMs in vitro (Fig.18) and comprised AAV2/6 and AAV2/9 virus pseudostrains. 
Moreover, cardiomyocyte and endothelial cell transduction was improved in vivo (Fig. 
26). Surprisingly, the liver did not display unequivocal results, showing enhanced 
transduction after G2 than G5 coated AAV2/9 transduction. 
Taken together, this observation is in accordance with results from the tumor field, that 
PAMAM dendrimers facilitate entry into cells which otherwise escape drug therapy, 
with either antibody or siRNA or pharmacological agents (lit. Wang C et al., Sci Rep 
2015 [61]; Ionov M et al., Int J Pharm 2015 [62]; Khatri S et al., J Pharm Bioallied Sci 
2014 [63]). However, it should be noted that these biodegradable organic nanoparticles 
contain biotoxicity, as observed in a topical skin application model recently (Winnicka 
K et al., Drug Des Devel Ther 2015 [64]) or in vitro cell culture systems (e.g. Movellan 
J et al., Macromol Biosci 2015 [65]). These observations may explain why a higher rate 
of dTomato mice was lost during the 21d follow up after transduction when G2 
PAMAM nanoparticles were applied (data not shown). However, this study was 
intended as a proof of principle study, with the concern of biosafety lying still ahead. 
4.2. Negative selection by surface-displayed endothelial-targeting 
peptides 
Previously, Varadi K et al. (Varadi K et al., Gene Therapy 2012 [24]) studied peptide 
modification of the AAV2/9 virus envelope in vitro and reported a ca. 200 times higher 
transfection efficacy with expression of the SLRSPPS peptide 
(Ser-Leu-Arg-Ser-Pro-Pro-Ser) than the native envelope in vitro. However, when used 
in vivo, this virus-peptide combination (termed EndoCre in our study, cooperation OJ. 
Müller, Heidelberg) did not transduce endothelial cells of the coronary (Fig. 27 & 29) or 
peripheral microcirculation (Fig. S7) beyond the rate of AAV2/9 wildtype transduction. 
Thus, a positive selection towards the endothelial cell compartment was not provided by 
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the SLRSPPS peptide expressed directly on the surface of an AAV2/9 virus envelope. 
This result confirms the ambiguous results previous attempts to achieve AAV-based 
microvascular endothelial transduction by direct capsid modification (Nicklin et al., 
Work et al., Müller et al.) and points to a difference between micro- and macrovessel 
transduction (e.g. umbilical veins, cf. Varadi K et al., Gene Therapy 2012 [24]) provided 
by the same vector. 
On the other hand, modification of the virus envelope by surface expression of the 
SLRSPPS peptide (=EndoCre) sufficed to disrupt cardiomyocyte transduction efficacy 
of the AAV2/9. The cardiomyocyte compartment was shielded from the 
SLRSPPS-modified envelope of the vector (cf. Fig. 27 C, D), pointing to a negative 
selection provided by this capsid modification. This finding confirms the fact that 
envelope structure is decisive for the myotropism of the AAV9 serotype, whose 
envelope is used in the AAV2/9 pseudotype virus. 
4.3. Peptide selection for endothelial targeting 
Since other peptides displayed limited efficacy in vivo, we decided to perform our own 
selection of an endothelial affine peptide. We chose to select for transduction of human 
endothelial cells (umbilical vein-derived = HUVECs and microvascular = HMECs). An 
own phage display selection experiment using the M13 CX7C (C; cystein, X; random 
7-mer aa) phage display library system (Fig. 19 - 21), followed by 3 rounds of 
biopanning in an endothelial cell culture (cf. Methods, 2.2.4. panning) yielded 10 
peptides. After comparison of both, HUVEC and HMEC transduction as well as 
homology screening (Fig.21, Table 4), Peptide 3 (CNNSGMRN) was selected. For 
comparability reasons, we used the SLRSPPS peptide from O. Müller (Heidelberg) as a 
control peptide. 
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Figure 31 | Schematic representation of cellular uptake by AAV/PAMAM complexes. a, AAV/G2 
PAMAM or AAV/surface modified-G2 PAMAM complexes. b, Cell membrane targeting by a complexes. 
c, The cellular uptake in endothelial cell [56]. G2: generation 2 PAMAM, G5: generation 5 PAMAM, 
AAV: adeno associated virus. 
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4.4. Positive selection by PAMAM-linked endothelial targeting 
peptides 
In a next step, targeting of endothelial cells was successfully performed with achieved 
with the endothelial cell binding peptide P3 (Asn-Asn-Ser-Gly-Met-Arg-Asn: 
NNSGMRN), covalently coupled to the G2 PAMAM via a 2 kDa PEG linker (Fig. 31). 
After combining our own selected P3 with PAMAMs using the PEG-linker, we found 
for the first time a positive selection effect on endothelial targeting in vivo in coronary 
microvessels (Fig. 27 & 28). A similar, though slightly less efficient transduction was 
found, when SLRSPPS (=P1) was linked to PAMAMs, which then were fused to the 
AAV2/9 envelope. 
It is noteworthy that most of the difference obtained between the EndoCre vector 
(expressing P1 on the surface of the virus envelope) and the AAV/G2P1 vector 
(displaying P1 on the G2 PAMAM) mainly was the localization of the P1 peptide. Thus, 
we could demonstrate with the same targeting peptide, that presentation on the tip of a 
positively charged nanoparticle is superior to the presentation on the virus envelope. 
Further studies are required to assess whether the positive charge is the main targeting 
virtue of the nano-particle or whether other (molecular) mechanisms are involved in 
increasing the transduction efficacy of endothelial cells. 
Of note, PAMAM surface modified vectors (Cre/G2P1 and Cre/G2P3) did not lose their 
ability to efficiently transduce cardiomyocytes. This observation stands in contrast to 
the weak cardiomyocyte transduction of EndoCre vectors and points to a two step 
model of virus transduction: whereas the AAV2/9 coat itself suffices for high 
cardiomyocyte affinity, direct virus coat modification with P1 (=EndoCre) disrupt this 
behavior (negative selection). However, the repulsion of vectors from cardiomyocytes 
in itself does not increase endothelial transduction. For this process, positive selection 
towards endothelial cells is needed, e.g. by a combination of nano-particles with 
endothelial targeted peptides (e.g. Cre/G2P3 or Cre/G2P1). In future work remodeling 
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surface of the nano-particles may optimize our approach, such as a half side displayed 
cationic PAMAM dendron is coupled with another half side displaying the 
endothelial-targeting peptides (P1 or P3). 
4.5. Endothelial targeting: Functional proof of transduction 
In previous study, the claim of endothelial transduction was derived from in vitro results 
and occasional fluorescence microscopy imaging. Rigid ex vivo tracing of transduced 
endothelial cells as well as functional in vivo bioassays were scarce. 
In order to improve accuracy of the claim of endothelial retargeting of an AAV, we 
developed two test systems: first, a FACS passed assessment of a 
transduction-dependent recombination event (Cre-based switch from red to green 
fluorescence) in CD31-positive cells digested from whole hearts of AAV-Cre transduced 
tomato mice (cf. Fig. 29). In this test system, we confirmed our fluorescence-imaging 
result in that the combination of G2 PAMAMs and P3 is efficiently transducing 
coronary microvascular endothelial cells to a higher extent than G2/P1. 
Second, we used a novel and unique test system. The basis of this system is an artificial 
adhesion molecule which – by virtue of its function, recruiting circulating CXCR4 
expressing cells, e.g. neutrophils – requires presentation on the luminal surface of an 
endothelial cell. The artificial adhesion molecule (S1FG) consists of a fusion protein 
coupling SDF-1/CXCL12 to the mucin backbone domain of fractalkine/CXCL12 and a 
GPI-membrane anchor. This artificial adhesion molecule has been shown to mediate 
adhesion of cells expressing CXCR4, the receptor for the SDF-1 ligand (Stachel G et al., 
Stem cells 2013 [55]). It consists of an SDF-1 chemokine head fused to the mucin 
domain from fractalkine/CXCL12, which can provide leukocyte recruitment, and a 
GPI-membrane anchor allowing for firm attachment to the cell membrane, without an 
intracellular signaling domain (Stachel G et al., Stem cells 2013 [55]). 
SDF-1 is well known to mediate neutrophil recruitment via its receptor, CXCR4 
(Strydom N et al., Journal of Innate Immunity 2013 [66]; Liehn EA et al., J Am Coll 
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Cardiol 2011 [67]). We capitalized on the neutrophil-attracting function of this 
chemokine head by displaying it on an artificial adhesion molecule, which can only 
exert its purpose when displayed at the luminal site of the endothelium, but not when 
expressed on the myocytes, as usually accomplished by the unmodified AAV2/9. We 
followed this process by in vivo microscopy in the cremaster-muscle (cooperation M. 
Sperandio, WBEx LMU). According to our prediction of a significant increase of 
endothelial transduction of the AAV2/9-G2P3 compared to the unmodified AAV2/9 
pseudotype, neutrophil adhesion to the endothelium of cremaster arterioles was 
increased by 5.62 fold (Fig. 30). This proof of principle indicates that indeed we were 
able to display a functionally active adhesion molecule towards the blood flow, and 
thereby induced firm adhesion of circulating neutrophils. This proof of principle by far 
exceeds previous experimental approaches, usually histologies of reporter gene 
expression in anatomical positions suitable with the endothelial lining (White SJ et al., 
Circ 2004 [48]; Varadi K et al., Gene Ther 2012 [24]). Given notorious difficulties to 
properly identify endothelial cells without further markers from histological sections, 
functional testing of unequivocal endothelial properties might be viewed as a more rigid 
form of proof in this regard. 
In summary, we report retargeting of the myotropism of AAV2/9 by displaying 
endothelial-affine targeting peptides on G2-dendrimers which were fused to the AAV2/9 
capsid. G2-P3 fusion to AAV2/9 increased the endothelial transduction rate and 
provided a 5.6 fold increase of the functionally relevant endothelial expression of S1FG, 
an artificial adhesion molecule effective only when displayed on the luminal surface of 
the endothelial lining. 
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4.6. Endothelial targeting motif of P3 (CNNSGMRN) 
Having established a functional role of the newly found peptide CNNSGMRN, we 
further analyzed the potential molecular mechanism of its endothelial affinity. We found 
a distinct homology to Stabilin-2. 
The Stabilin-2 (as named STAB-2 or endothelial protein) is a high molecular-mass 
multifunctional transmembrane receptor protein which contains four repeat units (RU), 
each containing epidermal growth factor (EGF)-like domains (cell/matrix interactions), 
integrin-binding fasciclin 1(FAS1) domains (protein/protein interactions) and X-link 
domain (hyaluronic acid binding) in extracellular region. In more detail, four 
laminin-type EGF-like domains, seven fasciclin-like adhesion domains, three B-(X7)-B 
hyaluronan-binding domains, fifteen EGF-like domains, one X-link domain, and one 
transmembrane region located on the end of C-terminal (cf. Oliver Politz et al., 
Biochem J 2002 [68]; Kai Schledzewski et al., JCI 2011 [75]). The endothelial targeting 
peptide P3 (CNNSGMRN) is almost entirely homolog (5 of 6 AA) to the sequence 
located on the 4
th
 of RU laminin EGF-like domains of mouse Stabilin-2 (GenBank: 
AAL91684.2), as shown in Fig -32. 
Laminin is a major protein of the extracellular membranes that mediate cell adhesion 
and differentiation. Furthermore, Laminin EGF-like (known as a LE) domains are 
structural elements of membrane-bound proteins or proteins known to be secreted. They 
contain repeats of each laminin subunit and the 3D structure of this domain is similar in 
EGF-like module. The LE domain has been shown to bind with a high affinity to 
nidogen (a component of the basement membrane). 
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Figure 32 | Domain structure of mStabilin-2. (Modified from Oliver Politz et al., Biochem J 2002 [68]; 
Seung-Yoon Park et al., Mol Cell Biol 2008 [70]). 
 
The mSTAB-2 is primarily expressed at high level in the sinusoidal endothelial cells of 
lymph node, liver, spleen, and low level in the heart. Comparison of the full length 
human protein sequences with mouse STAB-2 gave an identity of 71-79%, as human 
STAB-2 (cf. Oliver Politz et al., Biochem J 2002 [68]; Kai Schledzewski et al., JCI 2011 
[75]). It exerts functions in angiogenesis, receptor scavenging, lymphocyte homing, 
phagocytosis and cell adhesion (cf. MY Jung et al., Journal of Leukocyte Biology 2007 
[69]). The protein interacts with the integrin αMβ2 or αvβ5 which mediate lymphocyte 
adhesion to the liver sinusoidal endothelium or engulfment of phosphatidylserine 
(abbreviated Ptd-L-Ser or PS) exposed erythrocytes (cf. Sandra J. Stoll et al., PLOS 
ONE 2013 [71]; Kim S et al., Mol Cell Biol 2012 [72]; Sung-Jin Lee et al., BLOOD 
2011 [74]). It binds to and mediates endocytosis of hyaluronic acid (Megan S. Rost et 
al., PLOS ONE 2013 [73]; Kai Schledzewski et al., JCI 2011 [75]), and binding to PS 
receptor enhances the engulfment of apoptotic cells and critical anti-imflammatory 
fuctions of macrophages (Park SY et al., Mol Cell Biol 2008 [70]; Kim S et al., Mol 
Cell Biol 2012 [72]). Additionally, it acts as a scavenger receptor for dermatan sulfate 
(DS), non-glycosaminoglycan (GAG), acetylated low-density lipoprotein (AcLDL), 
chondroitin sulfate (CS), pro-collagen propeptides and advanced glycation end products 
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(AGE), and heparin (Hep). The protein was shown to exer several functions in 
application studies, such as Stabilin-2/HARE mediates systemic clearance of multiple 
glycosaminoglycans (GAGs) from the vascular and lymphatic circulations. Furthermore, 
the HA-NPs (HA/nanoparticle complex) study showed the atherosclerotic area via the 
active targeting procedure. It has been expecting to high potential as the carrier for 
diagnosis and therapy of atherosclerosis (cf. Lee GY et al., Biomaterials 2015 [76]). 
Additionally, the endothelial cell target P3 has homologs located on other proteins, such 
as neuromedin-B receptor (NMBR), transcription factor AP-2-beta (AP2B), TP53-target 
gene 5 protein (T53G5), and huntingtin-interacting protein M (HYPM), as shown in 
Table 5. 
 
Name Term 5’- aa sequence -3’ Length SP ID 
Peptide no.3 P3 1 CNNSGMRN 8 8 
 
Stabilin-2 STAB-2 1978 CNNRGM.. 1983 2559 Q8R4U0 
Neuromedin-B receptor NMBR 71 ..NSAMRN 76 390 O54799 
Transcription factor AP-2-beta AP2B 186 .NNSGM.. 190 459 Q61313 
TP53-target gene 5 protein T53G5 135 ...SGMRN 139 290 Q9Y2B4 
Huntingtin-interacting protein M HYPM 74 .NNGSMRN 80 117 O75409 
 
Table 5 | Other homologous sequence with P3. The under lines are indicate that unmatched aa 
sequences of endothelial target peptide no.3 compare with other candidate. SP ID; Swiss-Prot ID. 
 
Neuromedin-B receptor (NMBR) is a G protein-linked receptor (GPLR) which 
endogenous ligand is neuromedin B, such as a subfamily of mammalian bombesin-like 
peptides (cf. Corjay MH et al., J Biol Chem 1991 [77]; Sainz E et al., J Biol Chem 1998 
[82]). The NMBR binds NMB and regulates cell growth, blood pressure, 
exocrine/endocrine secretions, and glucose level. The receptor has highly affinity with 
mitogen and growth factor for normal and neoplastic lung. 
Transcription factor AP-2 beta (TFAP2B) is an activating enhancer binding protein 2 
beta) gene provides instructions for making a protein. A transcription factor is a protein 
that binds to specific regions of DNA and helps control the activity of particular genes. 
Transcription factor AP-2β is involved in development in the neural crest. Neural crest 
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cells migrate to form portions of the nervous system, glands that produce hormones, 
pigment cells, smooth muscle and other tissues in the heart, and many tissues in the face 
and skull. Transcription factor AP-2β also appears to play an important role in the 
development of the limbs. (Feng Zhao et al., Am J Hum Genet 2001 [78]; Shiro Maeda 
et al., J Hum Genet 2005 [79]). 
The p53 regulates growth arrest, tumor suppressor, and apoptosis mediated genes in 
response to stress signals. It is influencing programmed cell cycle, differentiation, death 
control mechanisms. TP53-target gene 5 protein (TP53TG5) also known as 
TP53-inducible gene 5 protein modulates p53 signaling pathways. This protein is highly 
expressed in brain, small intestine and heart (Isaka S et al., Genes Chromosomes Cancer 
2000 [84]). 
The hallmark neuropathology of Huntington’s disease (HD) is expansion of a 
polyglutamine segment in huntingtin. Huntingtin interacting protein M, as named 
HYPM, shown to interact with huntingtin. This protein contains a polyglutamine tract in 
Huntington’s disease. (Peter W. faver et al., Hum Mol Genet 1998 [80]). 
It remains to be determined whether P3 exerts its functions due to a Stabilin-2 like 
function, whereas due to location, time of expression, and type of distribution, other 
homologies like NMBR, TFAP2ß, TP53TG5 or HYPM appear as less likely candidates 
for functional homology. 
In summary, we report retargeting of the myotropism of AAV2/9 by displaying 
endothelial-affine targeting peptides on G2 or G5 PAMAM dendrimers which were 
fused to the AAV2/9 capsid. G2-P3 fusion to AAV2/9 increased the endothelial 
transduction rate and provided a more than 5-fold increase of the functionally relevant 
endothelial expression of S1FG, an artificial adhesion molecule effective only when 
displayed on the luminal surface of the endothelial lining. Thus, in this study we could 
demonstrate efficient expression of AAV-transduced genes of interest in vitro and in 
vivo. This finding could be of importance for further use of the AAV vector platform in 
a variety of experimental models and patient diseases, to provide for example vessel 
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growth (in ischemia) or vessel degradation (in tumor vessels) as well as vessel 
regulation (in endothelial dysfunction and vasospasm). 
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5. SUMMARY 
The identification of cell type specific binding ligands and improved transduction 
efficacy of vector systems (viral or non-viral) are needed for endothelial directed gene 
therapy. Adeno-associated viral (AAV) vectors are widely used for a long lasting 
efficacy and low immunogenicity. However, application of this vector in vascular 
biology is hampered by low transduction rates for vascular and particularly endothelial 
cells. Here, we attempted to enhance endothelium specificity of AAV based cardiac 
gene therapy via surface modification of the vector coat. Two principles were combined: 
first, a 7-mer endothelium targeting peptide, termed P3, was identified in biopanning 
with a CX7C phage library. Secondly, nanoparticles (generation 2 and 5 PAMAM 
dendrimers) were coated on the virus envelope surface. Combination of both approaches 
in an AAV2/9 G2P3 vector enhanced transduction in cardiac and skeletal muscle 
endothelial cells. Moreover, AAV2/9 G2P3 encoding for an artificial adhesion molecule 
(S1FG, cf. Stachel et al., Stem cells 2013) was efficient in recruiting circulating 
leukocytes in a cremaster intra vital microscopy model, whereas an unmodified 
AAV2/9 encoding for the same transgene did not yield this effect. These results appear 
as a proof of principle of AAV targeting towards endothelial cells and may have a broad 
range of applications in biotechnology and nanotechnology. 
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6. FIGUERS AND TABLES 
Figure.1 | Transmission electron microscopy image of AAV2 and Ad5. 
Figure.2 | Three-dimensional structure of AAV capsid and variable regions. 
Figure.3 | Cell entry and trafficking of AAV. 
Figure.4 | In vivo distribution of wild-type rAAV and rAAV mutant (R484E/R585E) in 
mouse tissues. 
Figure.5 | Schematic representation of polyamidoamine (PAMAM) dendrimers.  
Figure.6 | Factors affecting nanoparticle cellular uptake.  
Figure.7 | Schematic representation of cellular uptake of PAMAM dendrimer. 
Figure.8 | Structure of bacteriopahge.  
Figure.9 | Procedural of biopanning by phage-display library. 
Figure.10 | Design of gene delivery system by surface modified AAVs by different type of 
PAMAM dendrimers.  
Figure.11 | Construction of gene delivery viral vector and modifications by PAMAM with or 
without peptide linkage. 
Figure.12 | Cationic PAMAM dendrimers & surface modified PAMAM dendrimers. 
Figure.13 | Tomato reporter gene mice, mT/mG mutation mice; Gt(ROSA)26Sor. 
Figure.14 | Gene transduction by surface modified PAMAM coated AAVs in vitro and in 
vivo. 
Figure.15 | Identification of Cre expression in vivo. 
Figure.16 | Transduction efficiency characterization of AAV2/9-CMV-eGFP and 
AAV2/9-CMV-eGFP/PAMAM complexes in vitro. 
Figure.17 | AAV2 and AAV2/6 virus strains were incubated at 37°C/72 h with PAMAM 
G5. 
Figure.18 | Comparison of G2 vs G5 PAMAM coated AAV2/6-CMV-GFP in endothelial 
cells at 37°C/72 h. 
Figure.19 | Panning procedure of motif selection for targeting endothelial cells. 
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Figure.20 | Selected phages target to endothelial cell by Phage ELISA. 
Figure.21 | Graphical sequence logo representation of predominant motif. 
Figure.22 | Design of surface modified PAMAM dendrimers coated AAV2/9. 
Figure.23 | Transduction efficiency characterization of surface modified G2 with 
AAV2/9-CMV-eGFP complexes in endothelial cell. 
Figure.24 | Transduction efficacy of G5 in dTomato mice heart. 
Figure.25 | Transduction efficacy of AAV2/9Endo-Cre/G5 in dTomato mice heart. 
Figure.26 | Transduction efficacy of AAV2/9Cre/G2 or AAV2/9Cre/G5 in dTomato 
heart. 
Figure.27 | Transduction efficacy of AAV2/9Endo-Cre/G2 or AAV2/9Endo-Cre/G5 in 
dTomato mice heart. 
Figure.28 | Transduction efficacy of AAV2/9Cre/G2P1 or AAV2/9Cre/G2P3 in dTomato 
mice. 
Figure.29 | Whole heart analysis of dTomato mice by FACS. 
Figure.30 | Functionality of the S1FG fusion protein by intravital microscopy. 
Figure.31 | Schematic representation of cellular uptake by AAV/PAMAM complexes. 
Figure.32 | Domain structure of mStabilin-2. 
 
 
 
Table.1 | Characterization of viral vectors. 
Table.2 | Different type of non-viral vectors in gene delivery. 
Table.3 | Tropisms, receptors and co-receptors of AAV serotype vectors. 
Table.4 | Identification of homologous. 
Table.5 | Other homologous sequence with P3. 
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Fig S1 | Alignment analysis of peptide sequences. 
Fig S2 | AAV2/9Cre/G2 or AAV2/9Cre/G5 in elastic artery of dTomato mice. 
Fig S3 | AAV2/9Cre/G2 or AAV2/9Cre/G5 in hind limb of dTomato mice.  
Fig S4 | AAV2/9Cre/G2 or AAV2/9Cre/G5 in liver of dTomato mice.  
Fig S5 | AAV2/9Cre/G2 or AAV2/9Cre/G5 in kidney of dTomato mice.  
Fig S6 | AAV2/9Endo-Cre/G5 in elastic artery of dTomato mice.  
Fig S7 | AAV2/9Endo-Cre/G5 in hind limb of dTomato mice.  
Fig S8 | AAV2/9Endo-Cre/G2 or AAV2/9Endo-Cre/G5 in liver of dTomato mice. 
Fig S9 | AAV2/9Endo-Cre/G2 or AAV2/9Endo-Cre/G5 in kidney of dTomato mice. 
Fig S10 | AAV2/9Cre/G2P1 or AAV2/9Cre/G2P3 in elastic artery of dTomato mice. 
Fig S11 | AAV2/9Cre/G2P1 or AAV2/9Cre/G2P3 in hind limb of dTomato mice. 
Fig S12 | AAV2/9Cre/G2P1 or AAV2/9Cre/G2P3 in liver of dTomato mice. 
Fig S13 | AAV2/9Cre/G2P1 or AAV2/9Cre/G2P3 in kidney of dTomato mice. 
Fig S14 | AAV2/9Cre/G2P1 or AAV2/9Cre/G2P3 in brain of dTomato mice. 
Fig S15 | FACS in whole heart of dTomato mice. 
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7. APPENDIX  
7.1. Abbreviations 
A.U. 
 
astronomical unit 
Aa 
 
amino acid 
AAV 
 
adeno-associated virus 
ACE  
 
angiotensin-converting enzyme 
Ad 
 
Adenovirus 
APC  
 
antigen presenting cell 
ATP 
 
adenosine triphosphate 
bEnd.3 
 
mouse brain endothelial cell line 
BL  
 
Burkitt’s lymphoma 
bp  
 
base pair 
CAR 
 
coxsackie and adenovirus receptor 
cDNA  
 
complementary deoxyribonucleic acid 
CO2  
 
Carbondioxide 
DAB  
 
3,3’- Diaminobenzidine 
DAPI  
 
4, 6-diamidino-2-phenylindole 
DC  
 
dendritic cells 
dd  
 
double distilled 
DMEM  
 
Dulbecco’s Modified Eagle Medium 
DMSO  
 
Dimethylsulfoxide 
DNA  
 
deoxyribonucleic acid 
DTT 
 
Dithiothreitol 
E.coli  
 
Escherichia coli 
e.g. 
 
lat. Exempli gratia (“for example”) 
EDTA  
 
ethylenediaminetetraacetic acid 
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ELISA  
 
enzyme-linked immunosorbent assay 
FACS  
 
fluorescence-activated cell sorting 
FCS  
 
fetal calf serum 
FGFR 
 
fibroblast growth factor receptor 
FITC  
 
fluorescein isothiocyanate 
g  
 
Gram 
g.p. 
 
genomic particles 
G2 
 
generation 2 PAMAM dendrimer 
G2P1 
 
generation 2 PAMAM -PEG linker -Peptide no.1 
G2P3 
 
generation 2 PAMAM -PEG linker -Peptide no.3 
G5 
 
generation 5 PAMAM dendrimer 
GER  
 
Germany 
GFP  
 
green fluorescence protein 
Gp 
 
Glycoprotein 
h  
 
hour(s) 
H&E  
 
hematoxyline and eosin 
H2O  
 
Water 
HEK 293 
 
human embryonic kidney cell line 
HGFR 
 
hepatocyte growth factor receptor 
HL-1 
 
mouse cardiomyocyte cell line 
HMECs 
 
human microvascular endothelial cells 
HRP  
 
horseradish peroxidase 
HSPG 
 
heparan sulphate proteoglycan 
i.e. 
 
lat. id est (“that is”) 
Ig  
 
Immunoglobulin 
IL  
 
Interleukin 
IM  
 
infectious mononucleosis 
IPTG 
 
isopropyl-1-thio-β-D-galactoside 
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ITR 
 
inverted terminal repeat 
Kb 
 
kilo bases 
KCl  
 
potassium chloride 
kDa  
 
kilo dalton 
l  
 
Liter 
LB  
 
Luria Bertani 
LCL  
 
lymphoblastoid cell line 
LDL(R) 
 
low-density lipoprotein (receptor) 
LMP  
 
latent membrane protein 
M  
 
Molar 
MA  
 
muscular arteries 
mg  
 
milligram (1.0E-03 gram) 
MgCl2  
 
magnesium chloride 
MgSO4  
 
magnesium sulfate 
MHC  
 
major histocompatibility complex 
min  
 
minute(s) 
ml  
 
Milliliter 
MLV 
 
murine leukemia virus 
mm  
 
Millimeter 
mM  
 
Millimolar 
mRNA  
 
messenger ribonucleic acid 
Na2HPO4  
 
disodium hydrogen phosphate 
NaCl  
 
sodium chloride 
NaH2PO4  
 
sodium dihydrogen phosphate 
ng  
 
nanogram (1.0E-09 gram) 
nm  
 
Nanometer 
NPC 
 
nuclear pore complex 
nt  
 
Nucleotide 
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ºC  
 
degree centigrade 
OD  
 
optical density 
ORF  
 
open reading frame 
p.i. 
 
post infection 
p.t. 
 
post transduction 
PAMAM 
 
poly-amidoamine 
PBS  
 
phosphate buffered saline 
PCR  
 
polymerase chain reaction 
PE  
 
Phycoerythrin 
PEG  
 
Polyethylenglycol 
PEG linker 
 
NHS -PEG -OPSS linker  
PEI 
 
Polyethylenimine 
PFA 
 
Paraformaldehyde 
Pfu 
 
plaque forming units 
pg  
 
pictogram (1.0E-12 gram) 
PHA  
 
Phytohemaglutinin 
PI  
 
propidium iodide 
qPCR 
 
quantitative PCR 
rAAV 
 
recombinant adeno-associated viral vector 
RNA  
 
ribonucleic acid 
rpm  
 
rotations per minute 
RT  
 
room temperature 
RT-PCR  
 
reverse transcription-polymerase chain reaction 
scFv 
 
single-chain fragment of variable region 
SDS  
 
sodium dodecyl sulfate 
SMA  
 
alpha smooth muscle actin 
SOB  
 
super optimal broth 
SOT  
 
solid organ transplantation 
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TAE  
 
Tris acetate EDTA buffer 
TBS  
 
Tris buffered saline 
TBST  
 
Tris buffered saline tween-20 
TE  
 
Tris-EDTA 
TEMED 
 
N,N,N,N-tetramethylethlenediamine 
TFA 
 
trifluoroacetic acid 
TMB 
 
3,3’,5,5’-tetramethylbenzidine 
TNF-α  
 
tumor necrosis factor-alpha 
TR 
 
terminal repeat 
Tris 
 
tris(hydroxymethyl) aminomethane 
Tween-20  
 
polyoxyethylene sorbitane monolaurate 
U  
 
unit  
VCA  
 
viral capsid antigen  
Vp 
 
viral particle 
VP 
 
viral protein 
X-gal  
 
5-Bromo-4-Chloro-3-Indoyl-b-D-galactopyranosid 
μg  
 
microgram (1.0E-06 gram) 
μl  
 
Microliter 
μM  
 
Micromolar 
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7.2. Supporting informations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S1 | Alignment analysis of peptide sequences. Alignment analysis program is Clustal W 
program. For Fig 21. 
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Figure S2 | AAV2/9Cre /G2 or AAV2/9Cre /G5 in elastic artery of dTomato mice. The elastic artery of 
heart. The white arrows indicate Cre positive expression (green) endothelium in the tunica intima of artery. 
The white dashed lines are a area of Ad (adventitia of artery), M (media of artery), or L (lumen of artery). 
Scale Bar; 20 µm. For Fig 26.  
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Figure S3 | AAV2/9Cre /G2 or AAV2/9Cre /G5 in hind limb of dTomato mice. The artery (left), nerve 
(meddle), and myocyte (right) of the hind limb (merge images). The white arrows indicate Cre positive 
expression (GFP; green) in capillary. A (artery), N (nerve), M (myocyte) or C (capillary). Scale Bar; 20 
µm. For Fig 26.  
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Figure S4 | AAV2/9Cre /G2 or AAV2/9Cre /G5 in liver of dTomato mice. The liver of dTomato mice 
(merge images). A (artery). Scale Bar; 200 µm. For Fig 26.  
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Figure S5 | AAV2/9Cre /G2 or AAV2/9Cre /G5 in kidney of dTomato mice. The papillae (left), 
glomerulus (meddle), and renal artery (right) of the kidney (merge images). The white arrows indicate 
Cre positive expression (GFP; green) in glomerulus or renal artery. P (papillae), RP (renal pyramid), G 
(glomerulus) or RA (renal artery). Scale Bar; 100 µm. For Fig 26.  
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Figure S6 | AAV2/9Endo-Cre /G5 in elastic artery of dTomato mice. The elastic artery of heart. The 
white arrows indicate Cre positive expression (green) in the tunica intima of artery. The white dashed 
lines were indicate a area of Ad (adventitia of artery), M (media of artery), or L (lumen of artery). Scale 
Bar; 20 µm. For Fig 27. 
 
 
 
 
 
 
 
Figure S7 | AAV2/9Endo-Cre /G5 in hind limb of dTomato mice. The artery (left), nerve (meddle), and 
myocyte (right) of the hind limb. The white arrows were indicated Cre positive expression (GFP; green) 
in capillary. A (artery), N (nerve), M (myocyte) or C (capillary). Scale Bar; 20 µm. For Fig 27.  
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Figure S8 | AAV2/9Endo-Cre /G2 or AAV2/9Endo-Cre /G5 in liver of dTomato mice. The liver of 
dTomato mice (merge images). A (artery). Scale Bar; 200 µm. For Fig 27.  
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Figure S9 | AAV2/9Endo-Cre /G2 or AAV2/9Endo-Cre /G5 in kidney of dTomato mice. The papillae 
(left), glomerulus (meddle), and renal artery (right) of the kidney (merge images). The white arrows 
indicate Cre positive expression (GFP; green) in glomerulus or renal artery. P (papillae), RP (renal 
pyramid), G (glomerulus) or RA (renal artery). Scale Bar; 100 µm. For Fig 27.  
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Figure S10 | AAV2/9Cre /G2P1 or AAV2/9Cre /G2P3 in elastic artery of dTomato mice. The elastic 
artery of heart. The white arrows were indicated Cre positive expression (green) in the tunica intima of 
aortic artery. The white dashed lines were indicate a area of Ad (adventitia of artery), M (media of artery), 
or L (lumen of artery). Scale Bar; 20 µm. For Fig 28. 
 
 
 
 
 
 
 
 
 
 
Figure S11 | AAV2/9Cre /G2P1 or AAV2/9Cre /G2P3 in hind limb of dTomato mice. The artery (left), 
nerve (meddle), and myocyte (right) of the hind limb. The white arrows were indicated Cre positive 
expression (GFP; green) in capillary. A (artery), N (nerve), M (myocyte) or C (capillary). Scale Bar; 20 
µm. For Fig 28. 
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Figure S12 | AAV2/9Cre /G2P1 or AAV2/9Cre /G2P3 in liver of dTomato mice. The liver of dTomato 
mice (merge images). A (artery). Scale Bar; 200 µm. For Fig 28.  
 
 
 
 
 
 
 
 
Figure S13 | AAV2/9Cre /G2P1 or AAV2/9Cre /G2P3 in kidney of dTomato mice. The papillae (left), 
glomerulus (meddle), and renal artery (right) of the kidney (merge images). The white arrows indicate 
Cre positive expression (GFP; green) in glomerulus or renal artery. P (papillae), RP (renal pyramid), G 
(glomerulus) or RA (renal artery). Scale Bar; 100 µm. For Fig 28.  
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Figure S14 | AAV2/9Cre /G2P1 or AAV2/9Cre /G2P3 in brain of dTomato mice. The brain of 
dTomato mice (merge images). Scale Bar; 200 µm. For Fig 28.  
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Figure S15 | FACS in whole heart of dTomato mice. For Fig 29. 
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